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Abstract

Genetic factors account for 60-80% of variability in bone mineral density, and thereby
play an important role in predisposition to osteoporosis, a prevalent skeletal disease.
Understanding the genetic determinants underlying bone mass may improve prognosis
and provide novel targets for therapeutic intervention. Single nucleotide polymorphisms
(SNPs) associated with bone mass have been recognized in protein coding and noncoding genes, including microRNAs (miRNAs, miRs). Given the role of miRNAs as key
post-transcriptional regulators modulating skeletal phenotype, our goal was to investigate
the function of specific miRNAs in osteoblasts and osteoclasts, and understand how
SNPs can modify miRNA function.

A single nucleotide polymorphism in osteonectin 3’ untranslated region regulates bone
volume and is targeted by miR-433. The function of a bone mass associated SNP
(rs1054204, cDNA base 1599) in the 3’ untranslated region (UTR) of human osteonectin
gene was examined by developing and analyzing novel 3’UTR knock-in mouse models.
These studies demonstrated that rs1054204) alters osteonectin expression in bone and
leads to variability in trabecular bone volume. The underlying mechanism for SNP
modulation of osteonectin regulation may involve differential targeting by miR-433,
which is a negative regulator of osteoblast differentiation. rs1054204 also modulated

skeletal response to bone anabolic intermittent PTH. This work validates the association
of rs1054204 with bone mass, and assigns a physiological function to a common
osteonectin allele, providing support for its role in the complex trait of skeletal
phenotype.

Function of miR-365, -99b and -451 in osteoclasts. During RANKL induced
osteoclastogenesis in vitro expression of miR-365 and -99b is induced, while miR-451 is
downregulated. We demonstrated that miR-99b is a crucial positive regulator of
osteoclast differentiation, whereas miR-365 negatively regulates osteoclast formation.
Computational analyses predict mTOR, PI3 kinase/AKT, and calcium signaling pathways
to be top targets of miR-99b and -365 in osteoclasts. Following computational
predictions, we optimized a RISC immunoprecipitation protocol in osteoblastic and
osteoclastic cells, to identify miRNA targets in an unbiased manner.

Together our studies expand the current understanding of miRNAs in regulating skeletal
phenotype and contribute to the pool of SNP variants needed for individualized fracture
risk assessment.
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CHAPTER 1
Introduction
Genetic determinants of skeletal diseases: role of microRNAs

The skeleton is a unique organ, due to its diversity in function. It provides mechanical
support for muscular activities, physical protection to internal organs and serves as a mineral
repository for systemic homeostasis. Osteoporosis is a skeletal disease characterized by low bone
mass, deterioration of bone microarchitecture and decreased bone strength, causing bone fragility
and increased risk of fracture. Fracture is one of the leading causes of morbidity and mortality in
the elderly population. According to the National Osteoporosis Foundation (NOF), more than 9.9
million Americans over the age of 50 have osteoporosis and an additional 43.1 million have low
bone density. Assuming the same frequency of prevalence, NOF estimates ~20% increase in the
number of osteoporotic and osteopenic individuals by 2020 [1]. In order to create novel
therapeutics for bone loss and to identify risk factors for increased fracture prevalence, it is
important to understand the molecular mechanisms controlling the physiology of bone, as an
organ.

Bone formation
Bone is a highly dynamic tissue; during embryonic development cells forming bone are
derived from mesenchymal cells of the neural crest and lateral and paraxial mesoderm. The
neural crest cells give rise to the axial skeleton, while the lateral and paraxial mesoderm form the
appendicular skeleton [2]. Bone formation is initiated through condensation and subsequent
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differentiation of mesenchymal cells into osteochondral progenitors, which give rise to bone and
cartilage. Bone can be formed through two distinct processes, intramembranous and
endochondral ossification. In intramembranous ossification, osteochondral progenitors can
directly differentiate into osteoblasts, giving rise to the flat bones such as those in the
craniofacial region. While in endochondral ossification, which occurs in long bones, the
progenitors differentiate into chondrocytes that form a cartilagenous template, which is
subsequently replaced by bone.

Bone remodeling
Following bone formation, bone modeling is necessary for growth of the skeleton, and
determines the size, shape and density of bone. A second process, bone remodeling, is crucial for
mineral homeostasis, renewal of bone and repair of microdamage that can occur in response to
mechanical stress.

Bone remodeling, performed by teams of osteoblasts and osteoclasts, occurs in small
packets known as basic multicellular units (BMUs), and the cycle consists of 4 distinct phases:
activation, resorption, reversal and formation [3, 4]. Remodeling can be triggered either in
response to microdamage or by hormones and local factors in response to fluctuations in calcium
and phosphate homeostasis. Microdamage-induced bone remodeling is initiated by osteocytes
(mineralized osteoblasts) in proximity to the microcrack locus. This frequently results in
localized osteocyte apoptosis, activation of osteoblasts and recruitment of osteoclast precursors
to the resorption site. Activated osteoblasts express key cytokines that promote osteoclast
precursors to differentiate into mature bone resorbing osteoclasts. In addition, osteoblasts also
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secrete matrix metalloproteinases (MMPs), including MMP-13 that degrades osteoid on the bone
surface, thereby providing surface domains for osteoclast attachment (Figure 1.1).

Figure 1.1 Schematics of bone remodeling. Remodeling starts with osteocyte apoptosis and
RANKL

mediated

pre-osteoclast

recruitment

(Activation

Phase),

followed

by

osteoclastogenesis. Osteoclasts resorb bone (Resorption Phase) thus allowing the release of
factors usually stored in the bone matrix, which recruit osteoblasts in the reabsorbed area
(Reversal Phase). Once recruited, osteoblasts produce the new bone matrix, and promote its
mineralization (Formation Phase).

During the bone resorption phase, osteoclasts attach to the bone surface through the
sealing zone and enclose a resorption pit. Osteoclasts generate H+ and HCO3− ions through
carbonic anhydrase II enzyme activity; the H+ ions are secreted into the resorption pit through
the H+ATPase proton pump. HCO3− ions are pumped out of the cell by Cl−/HCO3− exchanger
leading to an increase in intracellular Cl-, which is secreted into the resorption pit by ClC-7
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(chloride channel type 7). The acidified environment created in the resorption pit leads to the
demineralization of bone matrix. Subsequently, proteolytic enzymes like Cathepsin K and matrix
metalloproteinases (MMP-9) degrade the organic phase of bone matrix. Following the
completion of resorption, osteoclasts undergo apoptosis, which marks the reversal phase. In this
phase, the irregular cavities formed from resorption are corrected and a ‘cement line’ is formed,
onto which osteoblasts can lay a uniform bone matrix. The exact details of this phase are not
clear. However, it may involve additional degradation of collagen and deposition of some
proteoglycans to form the cement line. It is also not clear whether macrophage or osteoblast
lineage cells play a role in the reversal phase. During the final “formation” phase of the
remodeling cycle, local osteoblast precursors are recruited to the resorbed site. Recruited
precursors undergo osteogenic differentiation and active mature osteoblasts deposit newly
synthesized osteoid at the resorbed site (Figure 1.1) [3, 4].

Osteoblasts
The bone forming osteoblasts are derived from multipotent mesenchymal stem cells with
the potential to differentiate into alternate fates including the adipogenic, chondrogenic,
myogenic and fibroblastic lineage. In response to appropriate stimuli, mesenchymal cells commit
and differentiate into osteoprogenitors that give rise to matrix synthesizing mature osteoblasts,
flat bone lining cells and matrix-embedded osteocytes. During osteogenic differentiation,
spindle-shaped osteoprogenitors transform into pre-osteoblasts that proliferate and differentiate
into osteoblasts. On the bone surface, osteoblasts appear as specialized cuboidal cells containing
large golgi apparatus, extensive endoplasmic reticulum network, and a unique plasma membrane
that enables them to synthesize and secrete a myriad of extracellular matrix proteins [5, 6].
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Depending on the developmental stage, the extracellular matrix proteins synthesized by
osteoblasts differ. For example, the pre-osteoblasts for the most part synthesize and secrete type I
collagen and fibronectin, while the immature osteoblasts secrete alkaline phosphatase. The more
mature osteoblasts secrete bone sailoprotein followed by osteocalcin, that associates with
mineralized matrix [5]. Osteoblasts exert a tight regulation on osteoclastogenesis; they can
promote osteoclast formation by expressing two crucial cytokines, macrophage colonystimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) [7, 8].
The former is necessary for proliferation and survival of osteoclast precursors, while the latter is
necessary for osteoclast formation. Osteoblasts can also inhibit osteoclast formation by
synthesizing osteoprotegerin (OPG, TNFRSF11B), a soluble decoy receptor for RANKL. OPG
inhibits osteoclastogenesis by blocking the RANKL-RANK interaction [8-10].

Osteoblast commitment and differentiation are intricately regulated by transcriptional and
post-transcriptional mechanisms. The two major transcription factors critical for osteoblast
commitment and differentiation are Runx2 and Osterix [11]. Runx2 belongs to the runt- domain
gene family and is crucial for osteoblastic commitment of multipotent mesenchymal cells
(MSCs) and bone development. While the globally Runx2 deficient mice have impaired
endochondral and intramembranous bone development, deletion of Runx2 in committed
osteoblast using 2.3kb-Col1a1-Cre leads to reduced postnatal bone growth [12-14]. Moreover,
deletion of Runx2 activity in mature osteoblasts using osteocalcin-Cre results in an osteopenic
phenotype with reduced osteoblastic activity [15, 16]. Osterix (Osx) belongs to the zinc finger
DNA-binding protein family of transcription factors and is crucial for osteoblastic lineage
commitment. Despite development of a cartilagenous skeleton, Osx-null mice lack bone and
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suffer embryonic lethality [11]. Osx acts downstream of Runx2 during lineage commitment;
deletion of Osx in committed osteoblasts (2.3kb-Col1a1-Cre) leads to osteopenia in growing
mice [17, 18]. These transcription factors are often elicited through key signaling pathways for
bone formation, including the BMP and Wnt pathways.

Bone morphogenetic proteins (BMP) are well known inducers of ectopic bone formation,
and are crucial for osteoblast commitment and function. Deletion of BMP-2/4 in limb bud
mesenchyme with Prx1-Cre leads to severe bone defects due to absence of osteoblast
differentiation. Similarly, 2.3kb-Col1a1- Cre driven BMP4 deletion in early osteoblasts results in
defective bone formation and growth. Moreover, overexpression of truncated dominant negative
BMPR-IB (BMP receptor), driven by the 2.3kb-Col1a1 promoter, leads to dwarfism with lower
bone volume and bone formation rate [19-23].

The importance of the canonical Wnt/β-catenin pathway is bone homeostasis was
demonstrated through identification of rare human mutations in the Wnt co-receptor LRP5 (low
density lipoprotein receptor related protein). LRP5 variants with a negative effect on Wnt
signaling can cause osteoporosis pseudoglioma, and variants positively affecting Wnt signaling
can cause Van Buchem disease and Sclerosteosis. Construction and analysis of LRP5-null mice
confirmed the role of this locus in bone mass, and allowed study of the underlying mechanisms
involved [24]. Moreover, Wnt/β-catenin signaling is essential for osteoblast lineage
commitment, which was demonstrated by Prx1-Cre driven-β-catenin deletion mouse, which
conditionally deleted β-catenin in limb mesenchyme. In these mice, the absence of β-catenin
blocked osteoblastic differentiation, and osteochondral precursors differentiated into
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chondrocytes instead [25, 26].

Osteoclasts
Multinucleated osteoclasts are hematopoietic lineage cells that originate from common
myeloid progenitors (CMPs) near the bone surface. Co-culture of bone marrow or spleen cells
with stromal cells led to the identification of M-CSF and RANKL as key cytokines for
osteoclastogenesis [27, 28]. These cytokines are sufficient and essential for recruitment of
osteoclast precursors, osteoclast commitment, survival, differentiation and function. Upon
commitment of CMPs to the osteoclast lineage, the mononuclear precursors proliferate, migrate
and fuse together to form multinucleated osteoclasts, that are subsequently activated to resorb
bone [29].
Activated resorbing osteoclasts are structurally distinct and undergo cytoskeletal
rearrangements during resorption, leading to their polarization and segregation of the plasma
membrane into special domains. Polarized osteoclasts reorganize their nuclei, endoplasmic
reticulum and golgi network towards the apical region of the cell, away from the resorption site.
In contrast, the numerous mitochondria, lysosomes and vacuoles are reorganized towards the
resorption site [29-31]. The plasma membrane in activated osteoclasts segregates into a
basolateral membrane, sealing zone, and a ruffled border surface. The basolateral membrane
faces the vascular marrow, while the sealing zone and the ruffled border face the bone surface.
Osteoclasts attach to the bone matrix through the sealing zone and some studies implicate
integrins like αvβ3 in mediating osteoclast attachment [32]. The sealing zone is enriched in
podosomes, which are foot-like projections that form actin rings. Formation of actin rings is
crucial for osteoclast attachment and resorption. The ruffled borders are finger-like membrane
projections that extend into the resorption pit and facilitate resorption. Ruffled borders are
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formed from the fusion of intracellular vesicles with plasma membrane, and are equipped with
ion transporters. Extensive vesicular trafficking through the ruffled border creates an acidic
environment in the resorption pit that leads to degradation of bone matrix [29, 32]. The ruffled
border also releases lysosomal enzymes like Cathepsin K that degrades the collagenous bone
matrix in resorption pit. The degraded bone matrix is taken up by osteoclasts through the ruffled
borders and released into the vascular marrow through the secretory domain of the basolateral
membrane (Figure 1.2) [29-31].

Figure 1.2 Mechanism of bone resorption by osteoclasts. Osteoclasts attach to the bone
matrix at sealing zones via αvβ3 integrins. Resorption is initiated by Carbonic anhydrase II
enzyme that generates H+ and HCO3− ions; H+ is transported into the resorption pit by
H+ATPase proton pump located in the ruffled border. HCO3− ions are exchanged for Cl− by
Cl−/HCO3− exchanger at the non-resorptive surface. Chloride channels (ClC-7) located in
the ruffled membrane pump the Cl− into the resorptive pit. Demineralized organic bone
matrix is degraded by cathepsin K, an acid protease and MMP-9 (matrix metalloproteinase
9) secreted into the resorptive pit.
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An early requirement for osteoclastic commitment of CMP is expression of transcription
factors PU.1, MITF (microphtalmia transcription factor) and c-Fos, which induce expression of
M-CSF receptor (M-CSFR) [28, 33-35]. M-CSFR belongs to receptor tyrosine kinase family and
upon ligand binding activates several signaling cascades including ERK and PI3K/ Akt pathways
for osteoclast precursor proliferation and survival [35]. M-CSF receptor binding also promotes
expression of RANK (RANKL receptor) by osteoclast precursors; thereby priming them for
RANKL induced osteoclastogenesis. Moreover, MCSF signaling also activates Rac, that
mediates osteoclast migration and resorption [36]. RANKL-RANK binding leads to recruitment
of adaptor proteins, TRAFs (tumor necrosis factor receptor associated factor), to activate several
signaling cascades. The two most well recognized are TRAF -2 and -6; together they activate
downstream signaling pathways of NF-κB, c-Jun N-terminal kinase (JNK), and NFATc1 [3739]. NFATc1 is one of the master transcription factors, activated by multiple signaling cascades
to induce osteoclastogenesis. Many studies have shown that NFATc1, in combination with PU.1,
MITF and NF-κB, induces expression of osteoclastic genes such as, Cathepsin K, Tartrateresistant acid phosphatase (Acp5, Trap), and Calcitonin receptor [40-42].

MicroRNAs (miRNAs, miRs)
More recently, the importance of the key post-transcriptional regulators, microRNAs
(miRNAs, miRs) in regulating bone cells has been appreciated. MicroRNAs are small,
endogenous, single-stranded RNAs that regulate expression of protein encoding genes. miRNAs
assembled in the RNA induced silencing complex (RISC) directly bind to the target mRNAs and
mediate downregulation of their expression by mRNA degradation and/or translational
suppression. For most part, miRNAs bind to the 3’ untranslated region (UTR) of target mRNAs,
however, miRNA binding sites can also be present in the coding region and 5’ UTR [43, 44].
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In osteoblasts, the importance of miRNAs was demonstrated by targeted deletion of the
key miRNA processing enzyme, Dicer, in osteoblast precursors using ColIa1-Cre, and in mature
osteoblasts using osteocalcin-Cre. Dicer deletion in osteoprogenitors prevents their
differentiation and impairs bone formation, leading to embryonic lethality. While Dicer deletion
in mature osteoblasts delayed their differentiation, and a high bone mass phenotype was
ultimately observed [45]. This suggests a temporal activity of miRNAs in bone formation.
Moreover, the importance of miRNA regulation in osteoclastogenesis was also demonstrated in
vivo in the Ctsk-Cre Dicer-null mice. Abrogation of miRNA biogenesis in osteoclasts resulted in
an osteopetrotic phenotype, with increased bone mass and decreased osteoclast number and
resorption activity [46]. Given the overall importance of miRNAs in bone biology, there is a
growing body of data describing the function of individual miRNAs in osteoblasts and
osteoclasts [47, 48]. However, there is little known about how sequence variants might impact
the activity of miRNAs in skeletal cells.

Sequence variations and gene regulation

Sequence variations such as insertions, deletions, copy number variants and single
nucleotide polymorphisms (SNPs) are responsible for genomic diversity. Recent studies have
identified approximately 38 million SNPs in the human genome, representing the majority of
gene variants [49]. Although most numerous, individual SNPs are small changes. Depending on
its location, a SNP may impact gene function or expression or it may be silent. For the most part,
determining the functional consequence of SNPs or other gene variants has lagged behind the
identification and cataloging of the sequence variants, themselves.
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In the field of skeletal biology, bone mass phenotype is known to be a complex and
highly heritable trait. Linkage studies, in conjunction with candidate gene studies, have identified
some rare genetic variants with a high impact on bone phenotype, most notably variants of
LRP5. More recently, GWAS (genome wide association study) has identified 62 genome-wide
significant loci associated with bone mineral density (BMD) [50, 51]. Some of these loci contain
candidate genes with known function in pathways important in bone physiology, such as
canonical Wnt signaling, the RANK-RANKL-OPG system, and endochondral ossification.
However, only chromosomal regions have been determined, and the genes or mechanisms
underlying the linkage with BMD are not yet identified. For the most part, the SNPs identified
are common variants, and likely have a small effect size. Presently, less than 6% of the variance
in femoral neck BMD can be explained by the GWAS-identified loci. [52].

It may be relatively straightforward to determine whether SNPs in the protein-coding
region of a gene, or within intronic areas that affect splicing, might cause changes in protein
function or abundance, and thereby, phenotype. However, the functional impact of SNPs in
untranslated regions (UTRs), promoter/enhancer regions or regulatory RNAs can be more
difficult to evaluate. Since only 1-2% of genome comprises protein coding sequence, it is
imperative to recognize and understand the potential function of SNPs in non-protein coding
regions. With regard to regulatory region SNPs and bone mass, the alpha 1 type I collagen
(Col1A1) gene was one of the first to be studied. In a cohort of post-menopausal women, BMDassociated SNPs in the promoter and intronic region of Col1A1 were reported. In vitro, these
SNPs were associated with altered bone matrix mineralization and collagen gene expression by
affecting binding of transcription factors, Nmp4/CIZ and Sp1, respectively [53-57].
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At conserved sites within the human genome, the largest proportion of variants is within
UTRs [49]. Remarkably, a study comparing GWAS-SNP sets found an enrichment of traitassociated variants in 3’ UTRs, compared with 5’ UTRs or coding sequences (CDS) [58]. The 3’
UTR is recognized as a critical control region, with the potential to regulate mRNA stability,
translation and localization. Moreover, many binding sites for microRNAs (miRNAs, miRs) are
found in 3’ UTRs.

SNPs and miRNAs

There are increasing reports of SNPs that can interfere with miRNA function. Such
polymorphisms can occur in the miRNA target site of a mRNA (miR-TS-SNPs) or in the
miRNA genes themselves (miR-SNPs) [59-61]. miR-TS-SNPs present at or near a miRNA
binding site in a protein coding gene could modulate miRNA function by creating or eliminating
a miRNA binding site in that target mRNA [62]. The functional impact of a miR-TS-SNP on
phenotype largely depends on whether the corresponding miRNA is expressed in a particular
tissue, as well as the expression of other possibly compensatory miRNAs. For example, miRs
and their targets can be expressed in a tissue specific manner, and a miR-TS-SNP might only be
of functional consequence if the targeting mRNA is expressed in the same tissue. These
considerations could provide some basis for understanding tissue-restricted phenotype associated
with some common SNPs. A recent study used an in silico approach to investigate potential
mechanisms for the association of certain SNPs in disease pathogenesis. They identified
potential pathways impacted by trait-associated 3’ UTR SNPs, as well as whether SNPs could
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affect splicing, polyadenylation site usage, secondary structure and miRNA binding [58]. This
approach can be utilized to analyze the available GWAS data to interpret biological relevance of
miR-SNPs in multifactorial diseases and outline novel pathways to explore experimentally [58].

In contrast to miR-TS-SNPs, SNPs in miRNA genes (miR-SNPs) are relatively rare. It is
estimated that only ~10% of human miRNA genes contain SNPs; and SNPs in the region
corresponding to the mature miRNA are the most rare (<~1%) [60, 63]. Since a single miRNA
could target hundreds of genes and regulate multiple pathways, a polymorphism in a miRNA
gene leading to functional impairment could impact all the regulatory pathways involving that
miRNA. Thus, there appears to be considerable selective constraint on the transmittance of miRSNPs.

In terms of trying to understand the function of mutations or polymorphisms in miRNA
genes and targets, the cancer field has been in the forefront. Because of such work, some miRTS-SNPs and miR-SNPs have become part of panels that can be used to help assess cancer risk,
prognosis and/or response to therapies [64]. Similar work in the field of skeletal biology is in its
infancy. However, some miRNAs and mRNA targets important in malignancy are also important
in bone or cartilage. Therefore, studies performed in the context of cancer can also be relevant
for understanding the function of miRNA gene and target polymorphisms in skeletal biology.
Accumulating evidence suggests that SNPs in human miRNA genes (pri-, pre- or mature) can
influence predisposition to skeletal disease, including osteoporosis. Although long non-coding
RNAs (lncRNAs) are also frequently targeted by miRNAs, contain SNPs, and can impact
skeletal physiology, there is relatively little known about the function of lncRNAs in the skeleton
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[65-67]. Consequently, in reviewing the published data on sequence variants in miRNAs and
miRNA targets, the following discussion will be restricted to protein coding genes and miRNAs
that could have an impact on the skeleton. Moreover, many studies have associated miRNA SNP
variants with a particular phenotype. However, few studies have identified a potential
mechanism involved. Therefore, this review will also be restricted to work demonstrating
molecular mechanisms.

miRNA biogenesis and function
Biogenesis of miRNAs is a complex, multistep process in which a long hairpincontaining transcript undergoes sequential maturation into a short single stranded miRNA. SNPs
or mutations that alter the sequence of the pri-miRNA can have a dramatic effect on processing;
therefore, before discussing SNPs in miRNA coding genes, it is important to first consider the
steps in miRNA biogenesis (Figure 1.3).

MicroRNA biogenesis most frequently begins with RNA polymerase II mediated
transcription of miRNA encoding genes into a long transcript termed primary miRNA (primiRNA). MicroRNA genes can reside in the intergenic regions of the genome, as well as within
the intronic and exonic regions of protein-coding genes [68]. Generally miRNAs in the same
cluster are co-transcribed, however additional post-transcriptional regulatory mechanisms exist
and may contribute to alterations in the expression profile of miRNAs in a cluster. Transcription
of intergenic miRNAs is regulated through dedicated promoters, while the intragenic miRNAs
can share promoters with host genes. However, recent evidence suggests that several intron-
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encoded miRNAs also possess independent promoters that are subject to classical regulation by
transcription factor binding, DNA methylation and histone modifications [69].

Figure 1.3 MicroRNA biogenesis pathway. Pri-miRNAs transcribed from miRNA
genes by RNA polymerase (Pol) II are processed into pre-miRNAs by
Drosha/DGCR8. Pre-miRNA is pumped into cytoplasm by XPO5 and further
processed into a miRNA duplex by Dicer/TRBP complex. The leading strand of
duplex that forms mature miRNA is indicated in blue. The mature miRNA strand
assembles with Ago, incorporated in the RNA-induced silencing complex (RISC).
Depending on the degree of complementarity of the seed sequence of miRNA and
3’UTR of the target mRNA, miRNA-RISC down regulates gene expression by
either translational repression or mRNA degradation.
XPO5-Exportin 5; DGCR8-DiGeorge syndrome critical region gene 8; TRBP-TAR
RNA binding protein; Ago- Argonaute; PACT, protein activator of PKR.
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Like any other Pol II transcript, the structure of pri-miRNAs is comprised of a 5’-cap and
3’-poly-A tail, which flanks 2 or more hairpin structures; and each hairpin consists of an
imperfect double stranded stem (~30 base pairs) and a short terminal loop. The pri-miRNA is
further sliced into a shorter (~60-80 base) hairpin structure termed precursor miRNA (premiRNA) by a Microprocessor complex. This complex includes two major proteins: DGCR8
(DiGeorge critical region 8) and Drosha (RNase III enzyme family). The DGCR8 protein
contains domains for binding Drosha and double stranded RNA, thereby recruiting the primiRNA to the Drosha RNase domain, which cleaves the pri-miRNA ~22 nucleotides upstream
from the base of the terminal loop stem [70]. The precision in Drosha mediated cleavage is
guided by unique motifs in the pri-miRNA (at the base and terminal loop of stem) and
discrepancies in the motif signature or length can result in varied pre-miRNAs [71-73]. The
Microprocessor complex also contains accessory proteins like DEAD-box helicases (p68 and
p72) that function as post-transcriptional regulators of miRNA biogenesis. For example, RSMAD interaction with the p68 helicase enhances pri-miR-21 processing by the Microprocessor
complex [74]. Although majority of pri-miRNAs undergo canonical processing, some miRNAs
bypass Drosha and are generated by alternative splicing of introns. (Figure 1.3) [75].

Following processing in the nucleus, pre-miRNAs are pumped to cytoplasm by exportin5 (XPO5), which binds to the stem of the hairpin and exports the pre-miRNA in a Ran-GTP
dependent manner [47, 76-78]. In the cytoplasm, pre-miRNAs are further processed into roughly
symmetric miRNA duplexes by the Dicer complex. This complex consists of proteins TRBP (Tar
RNA binding protein) and Dicer (RNase III enzyme family). The TRBP protein contains
domains for binding Dicer and the pre-miRNA. The Dicer/TRBP complex binds to the 2
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nucleotide long 3’ overhang of the pre-miRNA and cleaves 22 nucleotides upstream from the
base of the double stranded stem, resulting in formation of a miRNA duplex. Previously, the
Dicer RNase III enzyme was implicated to function only as a slicer but recent structural studies
indicate Dicer has an inherent capacity to selectively recognize and process diverse precursors.
Subsequently, the miRNA duplex is loaded onto a particular Argonaute protein (Ago 1-4,
typically Ago2) that, together with Dicer/TRBP, forms the RNA induced silencing complex
(RISC).

A single stranded mature miRNA is assembled from the RISC-miRNA duplex through
duplex unwinding and processing by Ago [69, 79-83]. In case of a perfect complementarity in
the center of the miRNA duplex, the mature miRNAs are formed through direct slicing by Ago2.
The passenger strand of the duplex often undergoes degradation; however in some cases both
strands of duplex are loaded into the RISC [84, 85]. Selection of the guide strand from the
miRNA duplex is governed by thermodynamics; the strand with the least stable 5’ end bases in
the duplex forms the mature miRNA that is loaded into RISC. Recent studies also suggest that
Dicer/TRBP interaction also partly influences that strand selection [86]. Interestingly, not all premiRNAs undergo Dicer mediated processing. For example miR-451 is processed from Ago2
mediated slicing of the pre-miRNA stem [69].

The RISC-Ago-bound mature miRNA binds to a complementary region on target
mRNAs, and the target binding is predominantly based on Watson-Crick base pairing. In
particular, complementarity of bases in the ‘seed’ region, nucleotides 2-8 in the 5’ end of the
miRNA, has been considered crucial for miRNA action [78, 87]. Non-canonical interactions in
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the seed region, consisting of G:U base pairing and bulges, were previously shown to
compromise miRNA targeting [88]. However, it is now evident that these non-canonical
interactions are indeed tolerated during miRNA-target binding [89]. Moreover, supplementary
base pairing within nucleotides 12-17 in the 3’end of miRNA can enhance miRNA target
recognition [90]. Interestingly, Ago2 has been reported to aid in miRNA binding site recognition,
due to its own, independent binding preference to selected mRNA sequence motifs [91].

miRNAs negatively regulate the expression of target mRNAs by repressing translation
and by decreasing mRNA stability [78, 92]. For the most part, the miRNA-RISC initially blocks
translation by inhibiting the function of cap-binding initiation factor eIF4E, reducing elongation
and enhancing translation termination, leading to formation of destabilized nascent peptides.
Recent studies also indicate that miRNAs mediate translation repression of target genes by
causing shortening of the poly-A tail. The destabilized transcripts with short poly-A tails are
subsequently deadenylated, decapped and degraded [93]. MicroRNA mediated mRNA
degradation is achieved by hydrolysis of phosphodiester backbone of target mRNA and
altogether both mechanisms lead to repression in gene expression [94]. Current studies indicate
that both translation repression and mRNA decay occur in conjunction during miRNA-mediated
post-transcriptional regulation [93, 95]. These reports indicate that during the early phase of
regulation, miRNAs repress translation, whereas mRNA decay might be the prominent
mechanism of miRNA mediated post-transcriptional regulation later [95]. In addition, there is
increasing evidence that selected miRNAs can be imported back into the nucleus, to alter the
processing or function of other miRNAs [94, 96].
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SNPs altering microRNA biogenesis and function

MicroRNAs regulate skeletal development and homeostasis by targeting multiple genes
and pathways. Thus, SNPs that alter expression and/or function of a single miRNA could
function as a dominant variant of skeletal phenotype. SNPs that compromise miRNA expression
can occur in the miRNA gene promoter, termed miR-P-SNPs, or in miRNA genes (miR-SNPs).
SNPs that compromise miRNA function can occur in the seed binding region of mature miRNA.

(I)

miR-P-SNPs: SNPs in miRNA promoters

miRNA promoters are regulated by mechanisms similar to those regulating promoters of
protein encoding genes. Following detection of transcriptional elements in pri and pre-miRNA
genes, transcription factor binding sites (TFBS) near promoters of several miRNAs have been
recognized [97, 98]. SNPs in these TFBS can modulate miRNA expression by, (1) altering the
binding affinity of TFBS to transcription factors or (2) abolishing an existing TFBS or (3)
creating a novel TFBS (Figure 1.4). With the discovery of many more SNPs in human miRNA
genes, databases like miRGen 2.0 and dPORE-miRNA were developed to bioinformatically
predict SNPs in miRNA promoters. Such studies estimated that ~20,000 SNPs prevail in human
miRNA promoters [99, 100]. Despite these elaborate predictions, information on the impact of
miR-P-SNPs on disease risk is limited. The mechanism by which miR-P-SNPs affect miRNA
regulation is known for only a few miRNAs.
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As an example, let us consider the impact of miR-P-SNP rs57095329 on miRNA
regulation. This SNP is located within 1 kb of the miR-146a transcription start site and was first
identified as strongly associated with risk of SLE (systemic lupus erythromatosis), a chronic
autoimmune disorder [101]. This association was later validated in a meta-analysis of GWAS
that included cohorts of European and Asian descent [102]. The studies in SLE linked the riskassociated minor allelic variant rs57095329-G (A>G, minor allele frequency (MAF) 0.14 in 1000
Genomes Project) with reduced miR-146a promoter activity, leading to low mature miRNA
levels. Moreover, the risk allele was also shown to reduce binding affinity of Ets1 to the miR146a promoter [101]. In bone, the Ets1 transcription factor, which enhances miR-146a promoter
activity, is also known to interact with CbfA1/Runx2, which is the quintessential factor for
osteogenesis [119].

Figure 1.4 Schematics of miR-P-SNPs. SNPs in the regulatory transcription factorbinding site (TFBS) near the promoter of miRNA gene can alter miRNA expression.!

Overall this study demonstrated that the miR-P-SNP modulated transcription factor
binding to miR-146 promoter thereby altering its expression. Interestingly, apart from SLE, miR-
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146a has been also implicated in rheumatoid arthritis (RA), an autoimmune disease affecting
skeletal tissues [103-105]. In RA, where joint destruction occurs due to chronic inflammation,
miR-146a has been shown to suppress osteoclastogenesis [104, 105]. However, an association
between the SLE-linked miR-P- SNP, rs57095329, and RA has not yet been examined.

(II) miR-SNPs: miRNA gene SNPs
The multistep processing of long transcripts into short miRNAs relies heavily on the
secondary structure of each transcript. Polymorphisms in miRNA genes that modulate RNA
secondary structure can impair subsequent processing, and reduce mature miRNA levels (Figure
1.5).

Pri-miR-SNP:
Mechanistic studies examining the effect of a pri-miRNA SNP on processing have been
described for miR-125a. SNP rs12975333 (G>T), located in the stem region of pri-mi125a, has
been shown to modulate miRNA expression and activity. Specifically, the minor allele variant
(T) was shown to decrease binding of pri-miR-125a to the DGCR8 component of the miRNA
biogenesis machinery. This leads to defective pri- to pre-miR processing and low mature miR125a levels. Moreover, in congruence with the decreased expression of mature miRNA, an
increase in levels of miR-125a targets was also observed in rs12975333 (T) containing cells [59].

In addition to affecting processing, rs12975333 is retained by the mature-miRNA and
was shown to impair miR-125a-mediated translational repression. Specifically, the T variant of
rs12975333 impairs the seed-binding region of miR-125a, and reduces repression on the miR-
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125a target gene, Lin-28 [59]. Lin-28 is a RNA binding protein that acts as a translational
enhancer of IGF2 [106]. Remarkably, such SNPs that reside in the seed-binding region of mature
miRNAs are quite rare, which might reflect their profound impact on cell physiology (Figure
1.5) [60, 61].

Figure 1.5. Schematics of miR-SNPs. SNPs in pri- and pre- and mature miRNAs are
likely to affect miRNA processing and subsequent mature miRNA levels. SNPs in mature
miRNA can alter their activity.
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Pre-miR-SNP:
One example of a pre-miRNA SNP that can modulate mature miR expression and
activity is illustrated by SNP rs2910164 in pre-miR-146a. SNP rs2910164 (G>C, MAF 0.458 in
CSAgilent Project) was mapped to the passenger strand in the stem in pre-miR-146a, and was
associated with the risk of various cancers, such as papillary thyroid carcinoma (PTC), prostate
cancer, breast cancer, gastric cancer, ovarian! cancer, esophageal squamous cell carcinoma,
hepatocellular carcinoma [107-113]. The mechanism for SNP rs2910164-mediated alterations in
mature miR-146a levels has been examined in studies of PTC and nasopharyngeal carcinoma
(NPC), where GC heterozygosity was linked to high PTC risk, while C allele homozygosity has
been associated with increased NPC risk [108, 114]. In both PTC and NPC, the risk associated
allele C resulted in lower miR-146a levels, due to impaired Drosha-mediated processing of the
pre-miRNA. Apart from impairing Drosha processing, this SNP has been suggested to stabilize
the passenger strand leading to increased regulation of miR-146a target genes-TRAF6 and
IRAK1 (Figure 1.5). In PTC patients, GC heterozygotes were shown to generate two passenger
strands, -146a*G and -146a*C along with the leading strand [107]. It is possible that these
alternate passenger strands could target different mRNAs. Although rs2910164 was previously
linked to RA, a later meta-analysis disproved this association [115, 116].
Altogether, these seminal studies elegantly demonstrate the impact of miRNA- SNPs on
miRNA processing and targeting.

(III) miR-TS-SNPs: SNPs in miRNA target sites
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Polymorphisms in the miRNA target site (miR-TS-SNPs) can either abrogate an existing
miRNA binding site or create a novel site in the 3’ UTR of target genes. Compared with SNPs in
miRNA genes, miR-TS-SNPs in 3’ UTRs are more abundant [60, 61]. Again, studies in the field
of cancer genetics have led the way, with regard to identifying the function of miR-TS-SNPs in
several target genes with known functions in bone, such as BMPRI (bone morphogenetic protein
receptor I).

Figure 1.6. Schematics of miR-TS-SNPs. SNPs in miRNA target site (TS) can
strengthen or reduce binding between the miRNA and its mRNA target. Moreover, such
SNPs can create a novel site or destroy an existing target binding sites, ultimately
modulating target gene expression.

Bone morphogenetic proteins (BMPs) are bone anabolic factors critical for development
[117]. BMPs signal through their membrane bound receptors, BMPRI (IA and IB) and BMPRII,
which form a homo- or heterotrimeric complex on ligand binding and activate a canonical Smadmediated transcriptional program [118]. Both type I BMP receptors have distinct spatial and
temporal expression patterns during embryogenesis [119-121]. In osteoblasts, BMPRI-B is
crucial for commitment of mesenchymal precursors towards osteogenic lineage, while BMPRI-A
appears to direct them towards adipocytic fate [21, 22]. Conditional deletion of BMPRI-B in
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osteoblasts leads to decreased bone formation and growth [23]. Inhibition of BMP signaling can
also lead to osteopetrosis due to impaired osteoclastogenesis and resorption, thereby indicating
its importance in bone remodeling [20].
One case-control study linked SNP rs1434536 (C>T, MAF 0.404 in 1000 Genomes
Project) in the BMPR-IB 3’ UTR with increased risk of estrogen receptor-positive (ER+) breast
cancer [122]. Previously, increased BMPR-IB mediated signaling in ER+ breast carcinoma was
associated with high tumor grade, high tumor proliferation, cytogenetic instability and poor
prognosis [123]. Interestingly, this SNP rs1434536 showed strong linkage with cancer associated
SNPs from the CGEMS (Cancer Genetic Markers of Susceptibility) GWAS data set [122, 124].
Patients carrying the high risk rs1434536-T allele had increased BMPR-1B expression, and this
allele demonstrated impaired binding of miR-125b binding to the BMPR-IB 3’ UTR [122]. A
second study demonstrated a similar mechanism for the rs1434536-T variant and higher prostate
cancer risk [125]. Remarkably, the rs1434536-T allele was shown impart BMPR-IB mediated
protection against endometriosis, due to diminished miR-125b directed repression [126]. SNP
rs1434536-T is a common variant, and increased BMPRIB levels in individuals carrying this
allele might contribute to higher bone mass.

SNPs in miRNAs important in the skeleton

miR-146a:
The human miR-146 family consists of 2 distinct isoforms, miR-146a and -146b, that
have been mapped to human chromosomes 5q33.3 and 10q24, respectively [108]. miR-146a is
expressed in articular cartilage and femur, as well as in non-skeletal tissues including prostate,
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liver, breast, and hematopoietic cells [127-132]. An NF-κB binding motif near the transcription
start site (TSS) of miR-146a has been recognized, and factors including TNFα,
lipopolysaccharide or IL-1 β (interleukin-1β) have been shown to induce miR-146a expression
[130, 133]. In turn, miR-146a limits the inflammatory response by targeting TRAF6 (TNF
receptor associated factor 6) and IRAK1 (IL1 receptor associated kinase 1), which play a role in
activating NF-κB signaling [130]. In osteoclasts, TRAF6 and IRAK1 mediate IL-1β induced
activation of NF-κB signaling to promote osteoclast survival and activity [37, 134].

Figure 1.7 Potential model for miR-146a role in osteoarthritis. In early OA lesions, high
levels of miR-146a are detected, which can suppress SMAD4/TGF-β signaling and enhance
chondrocyte apoptosis. With progression of OA, miR-146a levels decline, which leads to
loss of IL-1 β regulation. With increased IL-1 β/NF-κB signaling, expression of MMPs and
ADAMTS5 is induced, while Col II and aggrecan expression is suppressed; together this
exacerbates cartilage matrix degradation.
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miR-146a has also been linked to the pathogenesis of osteoarthritis (OA) [133, 135, 136].
OA is characterized by the progressive degeneration of articular cartilage, primarily in response
to mechanical injury. Studies have reported high levels of miR-146a in articular chondrocytes
during the early stages of OA, whereas in the later stages, miR-146a levels decline [135-137].
miR-146a has been shown to target SMAD4, which might suppress TGF-β mediated
chondrocyte survival [135, 136]. In the later stage of OA, when the synovium is inflamed, miR146a is suggested to have a protective effect on articular cartilage by suppressing IL-1β signaling
via TRAF6 and IRAK1 targeting. With decreased IL-1β signaling, expression of cartilagedegrading enzymes (MMP13 and ADAMTS5) is suppressed, while expression of cartilage
matrix proteins such as aggrecan and type II collagen is highly induced [133].

miR-146a also plays a crucial role in regulating bone remodeling. It functions as a
positive regulator in osteoblasts that drives commitment of mesenchymal stem cells to
osteogenic rather than a chondrogenic fate. By targeting Smad 2/3, miR-146a regulates TGFβ
signaling and indirectly downregulates expression of chondrocytic marker Sox9, and upregulates
Runx2 [64]. In osteoclasts, miR-146a levels increase during differentiation, and miR-146a has
been shown to inhibit both TNFα and RANKL induced osteoclast differentiation by mechanisms
likely to include the targeting of TRAF6 and IRAK1, as well as other mRNAs [105, 138].

The miR-146a gene contains at least 2 functional SNPs. The SNP in the stem loop region
of pre-miR-146a, rs2910164, discussed earlier, is a common variant that alters miRNA
processing, whereas the miR-146a promoter SNP rs57095329 alters transcription factor binding.
In addition, other SNPs in the promoter region of miR-146a have been recognized (rs17057381,
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rs73318382, and rs6864584), although their function has not yet been ascertained. Given the role
of miR-146a in regulating inflammation, autoimmunity, and skeletal homeostasis, it will be
crucial to examine the functional impact of these other miR-146a SNPs, and determine whether
they might be associated with skeletal diseases such as osteoarthritis and osteoporosis [115, 116].

miR-125:
The human miR-125 family comprises of three homologs: miR-125b1, -125b2 and -125a.
Both miR-125b1 (on chromosome 11q23) and -125b2 (on chromosome 21q21) genes produce
identical mature miR-125b. The miR-125a gene is located on chromosome 19q13.41, within a
cluster also containing miR-99b and let-7e [59, 139].

Figure 1.8 Potential model for miR-125a role in osteoclasts. miR-125a may fine tune
osteoclast differentiation by regulating NF-κB and NFATc1 signaling. miR-125a has a feed
forward regulatory mechanism with the NF-κB pathway, while it shares a feed back loop with
NFATc1 signaling. miR-125a directly targets TRAF6 and TNFAIP3 genes crucial for both the
signaling pathways.

In bone, miR-125a plays a crucial role in osteoclastogenesis. Upon RANKL stimulation,
the p65 subunit of NF-κB has been shown to bind near the transcription start site of miR-125a
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gene cluster, resulting in its upregulated expression [138, 140]. As discussed above, miR-125a
negatively regulates NF-κB signaling by targeting the TRAF6 gene, thereby indicating a
feedback mechanism [141]. Moreover, NFATc1, a transcription factor crucial for
osteoclastogenesis, has been shown to repress miR-125a expression [141]. These data suggest
that miR-125a levels are stringently regulated in osteoclasts, and may fine-tune differentiation.
Impairment in miR-125a levels due to pri-miR-SNPs could modulate osteoclastogenesis and
disrupt the balance in bone remodeling.

The other member of miR-125 family, miR-125b, has been shown to act as a negative
regulator of osteoblastic differentiation by targeting the Cbf (core-binding factor) family
members Cbf β and Runx2 [142]. miR-125b levels plummet in response to BMP 2/4 induced
osteoblast differentiation [142, 143]. In congruence with its negative role, increased miR-125b
levels were detected in serum and bone samples of osteoporotic patients [144]. miR-125b has
been shown to confer protection against OA by directly targeting cartilage degrading enzyme
aggrecanase-1 (ADAMTS-4). Reportedly, IL-1β suppresses miR-125b levels and upregulates
aggrecanase-1 expression in OA chondrocytes [145].

Although 6 polymorphisms in pri-miR-125a (rs41275794, rs12975333, rs12976445,
rs10404453, rs78758318, rs143525573) have been reported, only one of these (rs12975333) has
been shown to be functional. In contrast, the miR-TS-SNP (rs1434536) in miR-125b binding site
of BMPR-IB, discussed above, has been shown to have a dramatic effect on gene expression and
disease progression [59, 146-149]. Given the function of the miR-125 family in both the
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osteoblast and osteoclast lineage, it is of interest to determine whether these validated SNPs
display any association with BMD.

miR-196a2:
The miR-196 family consists of 3 members, miR-196a1, -196a2, and -196b that are
embedded in the highly conserved clusters of Hox (homeobox) genes. Located on chromosome
17, the miR-196a1 gene is lies within the Hoxb cluster, miR-196a2 lies on chromosome 12
within the Hoxc cluster, and miR-196b gene lies within the Hoxa cluster on chromosome 7. miR196 isoforms show a high level of identity. Mature miR-196a isoforms are identical, while the
mature miR-196b differs by a single base from the -196a isoforms. This sequence similarity
suggests that they target same panel of mRNAs.

Hox genes regulate skeletal patterning and limb development by coordinating signaling
pathways including, retinoic acid, BMP and TGF-β signaling [150, 151]. It is known that miR196 family members play a crucial role in development of the axial skeleton, by regulating Hox
genes (Hoxb8, Hoxc8, Hoxd8, Hoxa7), fine-tuning levels of HOX proteins in a temporal and
spacial manner [152, 153]. miR-196a promotes commitment of mesenchymal stem cells (MSCs)
towards the osteoblast lineage by targeting Hoxc8 [154, 155]. In osteoblasts, Hoxc8 acts as a
negative regulator of differentiation and transcriptionally suppresses osteopontin (OPN). In turn,
BMP signaling represses Hoxc8 activity through SMAD1 interaction with Hoxc8, and relieves
repression on OPN transcription [156-158]. In addition to Hoxc8, miR-196a has also been shown
to target Hoxb7 in MSCs. Over-expression of Hoxb7 has been shown to enhance the
proliferative and osteogenic capacity of MSCs. In aging MSCs, an inverse correlation between
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the levels of miR-196a and Hoxb7 were attributed to decreased osteogenic differentiation [155,
159].

Two miR-196a2 promoter region SNPs (rs35010275 and rs12304647) and one SNP in
the pre-miRNA (rs11614913) have been studied in gastric cancer cohorts [160, 161]. Of these,
miR-P-SNP rs35010275 (G>C; MAF 0.28 in 1000 Genomes Project), mapped within 1 kb of the
miR-196a2 transcription start site, has been associated with gastric cancer risk in a Chinese
population [160]. High levels of miR-196a detected in these patients were linked to the riskassociated allelic variant (G). Functional analyses indicated that rs35010275 modulated the
interaction of nuclear proteins with DNA, leading to differences in miR-196a levels. Although
the transcription factor complexes interacting with the SNP rs35010275 region were not
identified, this study nicely demonstrates that the allele-specific differences in promoter region
of a miRNA gene can alter promoter activity and modulate miRNA expression [160].

Another variant in the miR-196a2 precursor rs11614913 (C>T MAF 0.334 in 1000
Genomes Project) was associated with breast cancer risk [162]. Specifically, the T-allele was
associated with decreased cancer risk and low miR-196a levels. Functional analysis revealed that
the T variant leads to decreased mature miR-196a without affecting the pre-miR-196a2 levels,
thereby indicating a miRNA processing defect [162]. Since Hox genes play a critical role in bone
and cartilage, these common miR-196a variants may have an impact on skeletal phenotype.
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miR-149:
The region encoding human miR-149 has been mapped to intron 1 of the glypican1
(GPC1) gene. This highly conserved miRNA is expressed independent of its host gene in a wide
variety of non-skeletal tissues [163]. In the skeleton, expression of miR-149 has only been
reported in chondrocytes, where it is upregulated in the presence of inflammatory cytokines IL1β, IL-6 and TNFα. Furthermore, miR-149 has been shown to directly target these inflammatory
cytokines in a feedback loop. In OA, dramatically decreased miR-149 expression has been
suggested to exacerbate the inflammatory response [164, 165].

So far two SNPs have been mapped to pre-miR-149 at rs2292832 (C>T MAF 0.387 in
1000 Genomes Project), and rs71428439 (A>G MAF 0.144 in 1000 Genomes Project). Although
the association of rs2292832 with cancer risk has been extensively studied, newer meta-analyses
do not suggest an association between this SNP and cancer risk, and functional evidence for
rs2292832 is lacking [166, 167].

In contrast, the mechanism for a SNP-mediated effect on gene regulation has been
elegantly described for rs71428439 in the context of myocardial infarction (MI). Specifically, the
risk associated variant rs71428439-G has been linked to decreased miR-149 expression. The
SNP was predicted to alter the secondary structure of the pre-miR, yielding a less stable premiR-149-G. Functional analysis revealed that rs71428439-G modulates the pre- to mature miR
processing, resulting in low levels of miR-149. In addition to defining mechanism, this study was
unique in that it demonstrated the impact of rs71428439 on MI susceptibility in vivo. In a mouse
model of MI, the infarct size and myocyte apoptosis was low in mice injected with precursor for
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the miR-149- rs71428439-A variant, assigning a protective function against MI to rs71428439A. This SNP is a common variant, and since miR-149 targets inflammatory cytokines, an
association between this SNP and OA phenotype might be likely.

miR-27a:
The human miR-27 family comprises of two family members miR-27a and b. miR-27a is
transcribed within a cluster on chromosome 19 that also contains miR-23a and miR-24-2, while
miR-27b is transcribed in cluster on chromosome 9 with miR-23b, miR-3074 and miR-24-1. The
mature miR-27a and b differ by only one nucleotide.

Figure 1.9 Potential model for miR-27a role in osteoblasts. miR-27 fine tunes osteoblast
differentiation by positively regulating canonical Wnt signaling and negatively regulating Runx2
activation. miR-27a targets inhibitors of canonical Wnt pathway, APC and sFRP1, as well as
promoters of Runx2 activity, SATB2 and Hoxa10.

In bone, miR-27 expression was reported to increase during osteoblastic differentiation in
vitro. The miR-27 family promotes osteoblastogenesis by directly targeting and suppressing
expression of inhibitors of Wnt/β-catenin signaling, sFRP1 (soluble frizzled related protein 1)
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and APC (adenomatous polyposis coli) [126, 127]. Moreover, Runx2 binding sites were
identified upstream of the transcription start site for the miR-27a cluster, where Runx2
negatively regulates its transcription. The miR-27a~miR-23a~miR-24-2 cluster was shown to
target SATB2, which interacts with Runx2 to promote bone formation. Inhibition of the miR27a~miR-23a~miR-24-2 cluster by Runx2 establishes a positive feedback loop [168]. In
addition, miR-27a has been shown to target Hoxa10, which promotes osteoblast differentiation
through Runx2-dependent and –independent mechanisms [169]. This provides another potential
mechanism for the pro-osteoblastic effects of miR-27a repression.

So far two SNPs have been reported in pre-miR-27a at rs895819 (A>G MAF 0.364 in
1000 Genomes Project) and rs11671784 (G>A MAF 0.007 in 1000 Genomes Project). Notably,
G variant of rs895819 has been associated with decreased risk of breast, renal and
nasopharyngeal cancer [170]. The G variant was shown to aberrantly increase miR-27 expression
in colorectal cancer, although the subsequent mechanism of SNP action was not validated [171].
Recent studies linking rs11671784 (G>A) to gastric cancer risk have elegantly demonstrated that
the SNP impaired miRNA biogenesis. The risk associated allele rs11671784-G was shown to
result in an aberrant processing of pre-miRNA leading to increase mature miR-27 levels.
Subsequent increase in gastric tumorigencity associated with G variant was attributed to
decreased expression of miR-27 target gene Hoxa10 [172].

miR-124:
Mature miR-124 arises from three different pri-miR structures encoded by independent
genes. Genes encoding miR-124-1 and miR-124-2 have been mapped to chromosome 8, while
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miR-124-3 gene is located on chromosome 20. Mature miR-124 is evolutionarily conserved and
highly expressed by neurons in brain [173]. In the skeleton miR-124 is expressed by both
osteoblasts and osteoclasts [174, 175]. In osteoblasts, miR-124 expression decreases during
differentiation and it negatively regulates osteoblast formation by targeting Dlx2, Dlx3 and Dlx5
genes that are critical for osteogenic commitment [175]. Notably, miR-124 has also been shown
to suppress expression of chondrocyte marker genes like Sox9 and Aggrecan [176]. In contrast,
miR-124 has been shown to increase dramatically during commitment of human mesenchymal
stem cells to adipocyte lineage [175]. Thus, miR-124 may promote adipogenic differentiation at
the expense of commitment to the osteo-chondral lineage. Interestingly miR-124 also suppresses
osteoclastogenesis by targeting NFATc1, key transcription factor in osteoclasts; it also reduces
osteoclast precursor proliferation and motility by targeting integrin B1 (ITGB1), RhoA and Rac1
[174]. In a rat inflammatory arthritis model, miR-124 injection was shown to ameliorate
progression of the arthritic lesion by decreasing osteoclast formation [177].

Polymorphism rs531564 (G>C MAF 0.130 in 1000 Genomes Project) was detected in
pri-miR-124-1 in a case-control Alzheimer’s disease (AD) study. Although the SNP was not
linked to AD, the study showed that pri-miR-124-1 rs531564–G variant led to decreased mature
miRNA levels, likely due to alteration of pri-miR secondary structure [178]. Since rs531564 is a
common variant, and because miR-124 impacts both osteoblast and osteoclast differentiation and
function, it will be of interest to determine whether this SNP might be associated with bone
phenotype.
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Implication of miRNA associated variants in skeletal diseases

The relationship of genetic variations or mutations affecting miRNAs on skeletal disease
risk and pathogenesis has only begun to be explored. As of today, there are only a handful
studies demonstrating the role of miR-SNPs and miR-TS-SNPs in skeletal diseases such as
osteoporosis and chondrodysplasia.

Osteoporosis is characterized by low BMD and increased fragility, [52]. Predisposition to
osteoporosis partly depends on BMD accrual, which is highly influenced by genetics [52, 179].
One recent study associated a miR-TS-SNP, rs6854081 T>G (MAF 0.0855 in 1000 Genomes
Project) located in the 3’ UTR of FGF-2 (fibroblast growth factor 2) with BMD in a cohort of
middle-aged Caucasian women. Using the poly-miRTS database, SNP rs6854081was shown to
potentially interfere with miR-146a and -146b binding to FGF-2 [180]. FGF-2 is a potent
mitogenic growth factor that is widely expressed in limb bud mesenchyme, chondrocytes,
osteoblasts, osteoclasts and adipocytes. In osteoblasts, FGF-2 positively regulates osteoblast
differentiation partly via Wnt signaling, and its absence leads to decreased bone mass [181-183].
Moreover, sustained FGF-2 signaling can also inhibit bone formation by maintaining osteoblastic
precursors in a proliferative state, thereby preventing their differentiation [181, 182, 184]. In
osteoclasts, FGF-2 also promotes recruitment of osteoclast precursors and their differentiation
[182, 183, 185].

The minor allele of rs6854081 (G) was associated with low BMD, and higher FGF-2
levels were observed in the low BMD patients compared high BMD subjects [180]. It was
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speculated that rs6854081G might relieve translational suppression of FGF-2, leading to
increased FGF2 levels and enhanced osteoclastogenesis. In this study, FGF2 was not
experimentally validated as a target of miR-146a and b, and it is possible that other miRNAs
could be involved. However, this study did report a FGF2 3’ UTR SNP and provided an
implication for the role of miR-TS-SNPs in mediating variations in BMD [180].

Interesting, another miR-TS-SNP rs1054204 C>G (MAF 0.387 in 1000 Genomes
Project), identified in the 3’ UTR of non-collagen extracellular matrix protein osteonectin
(SPARC), was recently associated with idiopathic osteoporosis [186, 187]. Using a novel set of
mouse knock-in models, the minor allelic variant rs1054204-G was shown to contribute
decreased levels of osteonectin, decreased trabecular bone volume, and a reduced bone-anabolic
response to intermittent PTH1-34 treatment [186, 187]. Moreover, in vitro studies demonstrated
a cell-autonomous effect of the variant on osteoblastic differentiation and mineralized matrix
production. In bone, osteonectin facilitates collagen fibril assembly and promotes osteoblast
commitment, differentiation, and survival [188, 189]. Global deficiency of osteonectin leads to
development of low turnover osteopenia, with decreased bone formation [190]. The minor allelic
variant rs1054204-G was shown to enhance osteonectin post-transcriptional regulation by
creating a novel miR-433 target site in its 3’UTR [187]. Overall, this study provided a
physiological function to a common miR-TS-SNP [187]. Other studies demonstrated that miR433 can inhibit osteoblast differentiation and target Runx2 [187, 191].

Another novel study associated a mutation in pre-miR-2861 with osteoporosis in one
kindred. miR-2861 is transcribed in a cluster with miR-3960, and this locus is found at
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chromosome 9q34.11. In bone, miR-2861 is expressed by bone marrow mesenchymal precursors
and osteoblasts; osteoclasts do not express miR-2861. During osteoblastic differentiation, BMP2
was shown to upregulate the miR-3960/2861 cluster and miR-2861 positively regulates
osteoblast differentiation [192]. In a mouse model, downregulation of miR-2861 expression by
systemic administration of a specific miRNA inhibitor decreased bone mass and osteoblast
activity [193]. Remarkably, miR-2861 was shown to target HDAC5. In bone, HDAC5 is known
to deacetylate Runx2, promoting its ubiquitin-mediated degradation. Thus, miR-2861 mediated
inhibition of HDAC5 increases Runx2 acetylation and induces BMP2 stimulated osteoblast
differentiation and function [194]. Moreover, subsequent studies revealed a positive feedback
loop between Runx2 and the miR-2861 cluster, induced with BMP2 mediated osteogenesis
[192].!

Functional analyses revealed that the mutation in the osteopenic kindred mapped to the
leading strand in the stem of pre-miR-2861, which caused decreased mature miRNA levels due
to reduced miRNA processing. High levels of the miR-2861 target gene HDAC5 were attributed
to decreased Runx2 protein in the bones of these patients. Although expansion of the linkage
study to include unrelated osteoporotic patients and healthy controls did not reveal the presence
of pre-miR-2861 mutations in either groups, this study highlights a functional miR-SNP variant
with a profound impact on bone mass [193].

Another mutation that affects miRNA-mediated regulation was recently identified in Xlinked Chondrodysplasia. Chondrodysplasias are genetic disorders of bone and cartilage, and can
be caused by defects in the differentiation and proliferation of chondrocytes or in the
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extracellular matrix of the cartilage. Phenotypically, this disorder is associated with
platyspondyly (flattening of vertebral bodies along the axial skeleton), rhizomelia (shortening of
femur and/or humerus), specific brachydactyly, hydrocephaly, facial dysmorphism and
microphtalmia. X-linked chondrodysplasias represent irregularities that are more prevalent and
severe in males [195]. A linkage study using X-linked polymorphic microsatellite markers
mapped the disease locus for X-linked chondrodysplasia to a pericentromeric region within
Xp11.3–q13.1 (Lod score = 3.30). The HDAC 6 gene was hypothesized to be a candidate gene in
this locus, and exon sequencing revealed a variant (c.*281A>T) in the HDAC6 3’ UTR [196].

In osteoblasts, HDAC6 is known to promote Runx2 activity by deacetylating and
decreasing transcription of the Runx2 repressor, p21WAF1 in pre-osteoblasts [197]. In articular
chondrocytes, primary cilia that respond to mechanical strain regulate hedgehog signaling and
indirectly decrease transcription of cartilage degrading enzymes (ADAMTS5, MMPs). Recent
findings suggest that aberrant activation of hedgehog signaling in osteoarthritis can be
suppressed by HDAC6-mediated disassembly of the primary cilium [198]. The HDAC6 variant
(c.*281A>T) was localized to a miR-433 seed binding region in the 3’ UTR, and was shown to
interfere with miR-433 targeting. It is likely that upregulated HDAC6 may indirectly inhibit
hedgehog signaling and lead to phenotypic defects of chondrodysplasias. Altogether, this study
had demonstrated that HDAC6 3’ UTR variant suppressed miR-433 mediated posttranscriptional regulation, causing overexpression of HDAC6 that could contribute to X-linked
chondrodysplasia [196].
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Table 1.1 Genetic variants associated with miRNAs

miR-

miRNAs

SNP #

Alleles

miR-146a

rs57095329

A>G

miR-196a-2

rs35010275

G>C

miR-125a

rs12975333

G>T

miR-124

rs 531564

G>C

miR-146a

rs2910164

G>C

miR-196a-2

rs11614913

C>T

T-reduced miR levels

[162]

miR-149

rs71428439

A>G

G-reduced miR levels

[199]

miR-27a

rs11671784

G>A

G-reduced miR levels

[172]

miR-2861 *

mutation

C>G

G-reduced miR levels

[193]

miR-125a

rs12975333

G>T

T- impairs miR binding to lin-28

[59], [147]

BMPR-IB

rs1434536

C>T

T-loss of miR-125b binding site

[122]

FGF-2

rs6854081

T>G

SPARC

rs1054204

C>G

G-creates miR-433 binding site

[187]

HDAC6 *

mutation

A>T

T-loss of miR-433 binding site

[196]

PSNPs

Description
G-decreased miR levels; TFBS
modification
C- decreased miR levels; TFBS
modification

Reference
[101]
[160]

Pri-miR
T-decreased miR levels; DGCR8
binding
G-decreased miR levels

[59]
[178]

Pre-miR

miR-

G-increased miR levels; stable
alternative passenger strands

[107, 108]

SNPs

mature-miR

miRTSSNPs

!

G-loss of miR-146a, -b binding
site
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[180]

Conclusions

A growing number of GWAS have associated genomic loci with BMD and fracture risk.
Within these intervals, SNPs in protein coding regions as well as UTRs and miRNA genes
should be considered for functional validation. To date, only a limited number of studies have
identified SNPs or mutations in miRNA genes and target binding sites relevant to BMD.
However, miR-associated SNPs (miR-P-SNPs, miR-SNPs and miR-TS-SNPs) validated in other
disease models have potential to inform studies of SNPs and bone mass. In particular, data on
functional miR-associated SNPs (collated from other diseases), along with miRNA-target coexpression information and quantitative trait locus (QTL) mapping could provide some direction
for investigation of miR-SNPs with the potential for relevance in skeletal diseases. Moreover,
newer sophisticated bioinformatic tools such as Patrocles and PolymiRTS can be used in
conjunction with existing GWAS data to determine whether a polymorphism of interest might
also be miR-TS-SNPs. Given the polygenic nature of skeletal diseases like osteoporosis, addition
of such miRNA-associated SNPs to the pool of existing BMD-associated SNPs could enhance
the prognostic potential, if functionally validated.

However, the majority of SNP variants are likely to have a small impact on BMD. In
addition to genetics, factors including age, lifestyle, hormonal status and co-morbidities can
greatly influence the risk for fracture. Assigning a function to miR-SNPs requires in vitro
studies, whereas assigning a physiological function to such SNPs could require in vivo mouse
models in which the influence of other, non-genetic factors impacting bone mass can be
minimized. The increased usage of genome editing technology, such as the CrispR-Cas9 system,
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for the generation of novel mouse models will likely be instrumental in driving this field
forward. However, to advance clinical application, it will be crucial to analyze functional miRassociated SNPs in larger and ethnically diverse populations. Moreover, it will likely be
necessary to examine a large number of SNPs to achieve a significant enrichment in fracture
prediction, compared with the prediction tools currently used. Nonetheless, it is a goal worth
pursuing, as the studies performed will provide key insights into the function of miRNAs in
skeletal tissue.

We summarized the mechanisms for miR-associated SNP regulation of miRNA function,
and provided evidence suggesting of potential impact that variants of several miRNAs might
have in regulating skeletal phenotype (Table 1.1). Lastly, we summarized the current findings of
known miR-associated SNPs or mutations in skeletal diseases. miRNA based therapeutics are in
clinical trials for selected malignancies, and the development of novel miRNA-based
therapeutics for bone repair and regeneration is underway. Information on miRNA function in
bone and cartilage, as well as information on genetic variants affecting miRNA function could
help the clinicians develop a better plan for individualized treatment as well as predict the impact
of drug efficacy, adverse reactions or toxicity along with disease risk.
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CHAPTER 2
Research Aims and Hypotheses

High throughput approaches such as gene expression microarray or RNA sequencing
have provided a wealth of information on how miRNA expression profiles change during the
course of bone cell differentiation. However, an understanding of miRNA function in the
osteoblasts or osteoclasts differentiation program remains largely undefined. Moreover, although
it is appreciated that single nucleotide polymorphisms (SNPs) can affect miRNA function, the
impact of such variants on skeletal phenotype is unknown. The overall goal of our studies is to
understand how specific miRNAs in regulate osteoblast and osteoclast differentiation and
function. Specifically, 1) we demonstrate that SNP in the human osteonectin 3’ UTR leads to
differential miR-433 targeting and regulates bone volume, 2) we identify the function of miR365 and miR-99b in osteoclastogenesis

Chapter 3: Specific Aim1
Previously, osteonectin 3’ UTR haplotypes that differed only at SNP 1599 (rs1054204)
were associated with bone mass in a cohort of patients with idiopathic osteoporosis [186]. We
hypothesized that SNP 1599 in the osteonectin 3’ UTR leads to differential miRNA targeting and
regulates bone volume. To test this hypothesis, we proposed the following aims:

(I)

!

To determine whether SNP 1599 modulates osteonectin expression.
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3’ UTR reporter constructs representing 2 SNP 1599 haplotypes will be transfected in
hFOB1.19 cells (human fetal osteoblasts cell line) and the effect of SNP 1599 on osteonectin 3’
UTR function will be examined using luciferase 3’ UTR reporter assays. The effect of SNP 1599
on osteonectin expression in bone will be examined in human osteonectin 3’ UTR knock-in
mice, by qRT-PCR and Western blotting.

(II)

To determine whether SNP 1599 affects miR-433 regulation of the osteonectin 3’ UTR.
Using a computational approach and luciferase 3’ UTR reporter constructs, we will

examine if SNP 1599 leads to differential targeting of osteonectin by miR-433. We will also
examine the regulation and function of miR-433 in osteoblast differentiation by qRT-PCR and
loss function studies.

(III)

To examine the impact of SNP 1599 on bone volume.
Using microCT and histomorphometry, the effect SNP 1599 on bone volume will be

examined in femurs of osteonectin 3’ UTR knock-in mice. The effect of SNP 1599 on osteoblast
differentiation and mineralization will be examined in bone marrow stromal cell cultures derived
from osteonectin 3’ UTR knock-in mice. Furthermore, the effect of SNP 1599 on intermittent
parathyroid hormone (PTH) induced bone anabolic changes were monitored by microCT and
histomorphometry.

Chapter 4: Specific Aim 2
Previously, we performed a microarray study examining the miRNA expression profile
during osteoclastogenesis in an enriched population of murine osteoclast precursors. This study
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suggested that expression of miR-365-3p, and -99b was highly upregulated in differentiating
osteoclasts, while miR-451 levels were downregulated [138]. We proposed the following aims to
validate the expression of these miRNAs and examine their function in osteoclast formation.

(I)

To determine function of miR-356-3p, miR-99b-5p and miR-451 in osteoclasts.
Using qRT-PCR, the expression pattern of miR-365-3p, miR-99b-5p and miR-451 will

be validated during early, middle, and late stages of osteoclastogenesis in cultures of murine
osteoclast progenitors enriched by depletion of B220+ and CD3+ lymphocytes. RANKL induced
expression of these miRNAs will be determined in primary murine osteoclast progenitors and
RAW264.7 cells (monocytic cell line). Function of these miRNAs in osteoclast differentiation
will be examined by TRAP staining osteoclasts obtained from the differentiation of primary
murine bone marrow monocyte cultures transfected with specific miRNA inhibitors or mimics.

(II)

To identify miRNA targets in osteoclasts.
Using computational prediction tools, a panel of genes potentially targeted by miR-365-

3p and miR-99b in osteoclasts will be assembled. In order to identify miRNA targets in an
unbiased manner we will optimize a RISC-RNA co-immunoprecipitation protocol for
osteoblastic and osteoclastic cells.

Together, these studies will expand our understanding of role of miRNAs in osteoblasts
and osteoclasts, and provide a how comprehensive view on how modulation in miRNA
regulation can impact bone phenotype.
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CHAPTER 3

A single nucleotide polymorphism in osteonectin 3’ untranslated region regulates bone
volume and is targeted by miR-433

Neha S. Dole, M.S.1, Kristina Kapinas, Ph.D. 1,Catherine B. Kessler, B.S.1, Siu-Pok Yee, Ph.D.2,
Douglas J. Adams, Ph.D.3, Renata C. Pereira, Ph.D.4, and Anne M. Delany, Ph.D.1

1

Center for Molecular Medicine, 2Gene Targeting and Transgenic Facility, 3Department of
Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT, U.S.A.;
4

Mattel Children’s Hospital, University of California, Los Angeles, CA, U.S.A.

Abstract
Osteonectin/SPARC is one of the most abundant non-collagenous extracellular matrix
proteins in bone, regulating collagen fiber assembly and promoting osteoblast differentiation.
Osteonectin-null and –haploinsufficient mice have low turnover osteopenia, indicating that
osteonectin contributes to normal bone formation. In male idiopathic osteoporosis patients,
osteonectin 3’ UTR single nucleotide polymorphism (SNP) haplotypes that differed only at
SNP1599 (rs1054204) were previously associated with bone mass. Haplotype A (containing
SNP1599G) was more frequent in severely affected patients, whereas haplotype B (containing
SNP1599C) was more frequent in less affected patients and healthy controls. We hypothesized
that SNP1599 contributes to variability in bone mass by modulating osteonectin levels.
Osteonectin 3’ UTR reporter constructs demonstrated that haplotype A has a repressive effect on
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gene expression compared to B. We found that SNP1599G contributed to a miR-433 binding site
and miR-433 inhibitor relieved repression of the haplotype A, but not B, 3’ UTR reporter
construct.

We tested our hypothesis in vivo, using a knock-in approach to replace the mouse
osteonectin 3’ UTR with human haplotype A or B 3’ UTR. Compared to haplotype A mice, bone
osteonectin levels were higher in haplotype B mice. B mice displayed higher bone formation rate
and gained more trabecular bone with age. When parathyroid hormone was administered
intermittently, haplotype B mice gained more cortical bone area than haplotype A mice. Cultured
marrow stromal cells from B mice deposited more mineralized matrix and had higher osteocalcin
mRNA compared with A mice, demonstrating a cell-autonomous effect on differentiation.
Altogether, SNP1599 differentially regulates osteonectin expression and contributes to
variability in bone mass, by a mechanism that may involve differential targeting by miR-433.
This work validates the findings of the previous candidate gene study, and it assigns a
physiological function to a common osteonectin allele, providing support for its role in the
complex trait of skeletal phenotype.

Introduction

Osteoporosis is a prevalent disorder characterized by low bone mineral density (BMD),
deterioration of bone microarchitecture and increased incidence of fracture [200]; and genetic
factors account for 60-80% of total variability in BMD [179]. Understanding the genetic
determinants underlying bone mass may improve prognosis and provide novel targets for
therapeutic intervention. In this regard, genome wide association studies (GWAS) and candidate
!
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gene studies have associated allelic variants of genes such as estrogen receptor (ER)-α,
transforming growth factor (TGF)-β, osteoprotegerin, and type I collagen A1 with bone mass
[201-205]. However, only a few studies have demonstrated a mechanism whereby a
polymorphism could contribute to bone mass phenotype. Indeed, a previous GWAS study in
premenopausal women linked variations in BMD to genomic regions including 5q33-35 [206].
Although candidate genes in the 5q33-35 interval were not identified, this region contains the
gene for osteonectin/Sparc (secreted protein acidic and rich in cysteine), one of the most
abundant non-collagenous extracellular matrix proteins in bone. In osteoblasts, osteonectin
promotes commitment, differentiation, and survival. Osteonectin also suppresses adipogenic
differentiation of mesenchymal precursor cells. In vivo, osteonectin-null and –haploinsufficient
mice develop low turnover osteopenia, characterized by reduced osteoblast and osteoclast
number and surface, and low bone formation rate [188, 189, 207, 208]. Moreover, osteonectinnull mice accumulate less bone in response to intermittent administration of parathyroid hormone
(PTH), the best bone-anabolic treatment clinically available at this time [208].

Based on these findings, we had previously performed a candidate gene study, to
determine whether 3 single nucleotide polymorphisms (SNPs) in the 3’ untranslated region
(UTR) of osteonectin (Figure 3.1A) were associated with bone mass in a cohort of men with low
turnover idiopathic osteoporosis, a disorder primarily attributed to genetic determinants [186].
Briefly, this cohort consisted of middle-aged Caucasian men with a BMD T score of less than 2.0 at the lumbar spine, who lacked known secondary causes for osteoporosis. The control
subjects were age and body mass index matched to the patients, and had BMD T scores of more
than 1.0 at the lumbar spine. As a group, the idiopathic osteoporosis patients had mean serum
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PTH and IGF1 levels in the low normal range. Their indices of bone formation were significantly
reduced, although eroded surface was not different between patients and their matched controls
[209, 210]. In the osteoporotic cohort, prevalence of fragility fracture was 23% [186].

In this cohort, one of the two most common osteonectin 3’ UTR haplotypes that we
identified, haplotype A, was found at a higher frequency in the most severely affected
osteoporotic patients, whereas the second most common haplotype, B, was found at a higher
frequency in the healthy controls. In addition, haplotype B was associated with higher BMD in
the patient population [186]. Osteonectin 3’ UTR haplotype A contained the SNPs at cDNA
bases 1046C_1599G_1970T, whereas haplotype B consisted of SNPs 1046C_1599C_1970T
(Figure 3.1A). Since these BMD associated haplotypes differed only at cDNA base 1599, we
hypothesized that SNP 1599 C>G (rs1054204) may impact osteonectin expression, and affect
bone mass. The 3’ UTR represents a powerful regulatory region, with the potential to modulate
mRNA stability, translation and localization [211]. Polymorphisms in the 3’ UTR have the
potential to alter the secondary structure of the mRNA, as well as its interaction with trans-acting
factors, such as microRNAs (miRNAs, miRs). miRNAs are small, endogenous non-coding
RNAs that, for the most part, decrease the stability and/or translation of protein-encoding
mRNAs. Recent studies have associated mutations or SNPs in miRNA binding with skeletal
disorders. For example, a SNP in the 3’ UTR of Fgf2 (fibroblast growth factor 2) that abrogates
miR-146a and -146b binding sites, was linked to low BMD in osteoporotic patients [180].
Another study attributed a mutation in the binding site for miR-433 in the 3’ UTR of Hdac6
(histone deacetylase 6) to the pathogenesis of X-linked chondrodysplasia [196].
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In this study we show that human osteonectin SNP1599 differentially regulates gene
expression and contributes to a miR-433 binding site. Specifically, 1599G, found in haplotype A,
has a repressive effect on gene expression and osteoblastic differentiation compared to 1599C,
which is found in haplotype B. Moreover, using novel knock-in mouse models, we demonstrate
that compared to mice carrying human osteonectin haplotype A 3’ UTR (SNP 1599G), mice with
the haplotype B 3’ UTR knock-in (SNP 1599C) have higher levels of osteonectin in bone, higher
bone formation rate, increased trabecular bone volume with age, and a greater increase in cortical
bone volume in response to the bone-anabolic PTH treatment. These data substantiate the
relationship between osteonectin 3’ UTR SNP 1599 and skeletal phenotype, validate our initial
observations in the cohort of idiopathic osteoporosis patients, and suggest that SNP 1599 affects
bone mass by modulating osteonectin expression.

Materials and methods

Generation of osteonectin 3’ UTR haplotype constructs.
1.1 kb variants of human osteonectin 3’ UTR (cDNA bases 1018-2123) representing
haplotypes A and B found in idiopathic osteoporosis patients were PCR amplified from genomic
DNA using appropriate primer sets (Forward: 5’-ggactagtatccactccttccacagtaccgaa-3’ and
reverse: 5’-cccaagctttgaaggatttgtgaaactcttcac-3’). Amplified fragments were cloned downstream
of the Luciferase gene in pMIR-REPORT vector (Life Technologies) using SpeI and HinDIII
restriction enzymes (Invitrogen). Haplotype 3’ UTR constructs were confirmed with sequencing.
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Cell Culture.
Human fetal osteoblastic 1.19 cell line (hFOB1.19) was purchased from American Type
Culture Collection (ATCC number CRL-11372). These cells are homozygous for human
osteonectin

3’

UTR

haplotype

C

(rs1053411G/C_rs1054204C/C_rs1059279G/G)

(our

unpublished data). hFOB1.19 cells were grown at 33.5º C in complete medium of 1:1 Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F-12 medium without phenol red (Invitrogen,
Fredrick, MD), supplemented with 10% fetal bovine serum (FBS) (Atlas Biologicals, Fort
Collins, CO), 0.3 mg/mL G418/ geneticin (Calbiochem, Gibbstown, NJ), and 1X
Penicillin/Streptomycin (Pen/Strep) (Invitrogen). hFOB1.19 cells were differentiated into
osteoblasts in vitro by culturing confluent cells at 39.5º C in complete medium supplemented
with differentiation cocktail: 100 µg/µL ascorbic acid, 10-8 M menadione (vitamin K), 5 mM βglycerolphosphate (β-GP), and 10-7 M 1-25(OH)2-Vitamin D3 (all from Sigma, St Louis, MO)
[212, 213].

Transfection and luciferase activity.
hFOB1.19 cells were seeded in 24-well plates and grown to 80% confluency prior to
transfection. Using Fugene6 (Roche, Indianapolis, IN), cells were co-transfected with luciferaseosteonectin 3’ UTR constructs (50 ng) and a constitutively expressed β-galactosidase (β-gal)
plasmid construct (100 ng), as a control for transfection efficiency (Promega). The ratio of
Fugene6 to DNA was optimized to 3:1. 18 hours post-transfection, cells were serum-deprived for
24 hours and lysed using Reporter Lysis Buffer (Promega). Luciferase activity (Luciferase assay
system, Promega) was determined and normalized to β-gal activity (Galacton chemiluminescent
assay system; Tropix, Bedford, MA). At least 2 different DNA preparations for each construct
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were tested. In addition, hFOB1.19 cells were co-transfected with luciferase-haplotype
constructs (25ng), β-gal expression plasmid (100ng) and miRNA inhibitors (80nM, Ambion)
using X-tremeGENE reagent (X-tremeGENE: nucleic acid ratio 5:1; Roche). A scrambled
miRNA inhibitor that does not interact with any known mammalian miRNAs was used as a
negative control (Ambion). 18 hours post-transfection cells were serum-starved for 24 hours,
lysed, and analyzed as described above. Each experiment was done with 4-6 replicates and at
least three independent experiments were performed. Representative experiments are shown.

Generation of osteonectin knock-in mice.
A knock-in strategy was used to replace the mouse osteonectin 3’ UTR with human
haplotype A or haplotype B 3’ UTR. These mouse models were generated at the Gene Targeting
and Transgenic Facility (GTTF) at UCHC. Briefly, human osteonectin 3’ UTR sequence
consisting of the 1 kb 3’ UTR, the consensus poly A site, and a G-T rich region was cloned into a
mini targeting vector containing a neomycin resistance cassette flanked by lox P sites and mouse
homology arms. The mini targeting vector was prepared in pL253 and recombined into a BAC
(bacterial artificial chromosome, Children’s Hospital Oakland Research Institute; BACPAC
Resources Center) [214]. The resultant targeting vector contained 8-10 kb long mouse homology
arms that enabled targeted insertion of human 3’ UTR into mouse osteonectin gene at exon 10, in
129 embryonic stem cells. Mice with osteonectin haplotype A (ON+/A) or haplotype B (ON+/B) 3’
UTR were crossed with Hprt-Cre transgenic mice, to excise the floxed neomycin cassette. ON+/A
and ON+/B mice were back crossed 7 times into C57BL/6J. ONA/B breeding pairs were
maintained to generate ONA/A and ONB/B mice for analysis.
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Quantitative RT-PCR analysis.
Femurs and tibiae of 6-8 week old ONA/A and ONB/B mice, devoid of marrow, were flash
frozen in liquid nitrogen and homogenized. RNA was extracted using miRNeasy mini kit
(Qiagen, Valencia, CA). RNA was also isolated from hFOB1.19 cells grown to confluence and
differentiated for up to 6 days. All RNAs were subjected to RQ1 DNase I treatment to minimize
genomic DNA contamination (Promega, Madison, WI). miR-433 levels were determined using
the TaqMan MicroRNA assay (Life Technologies, Grand Island, NY). miRNA levels were
normalized to RNU48 (small nuclear RNA) in hFOB cells and to sno202 RNA in mouse BMSCs
or bone extracts (recommended endogenous control for mice and human tissue by TaqMan
MicroRNA assay).
Table 3.1. Primer sequences used for qPCR analysis.
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Gene (m- mouse, h-human)

Sequence

h OC (sense)

5’-ACACTCCTCGCCCTATTG-3’

h OC (antisense)

5’-GATGTGGTCAGCCAACTC-3’

h ALP (sense)

5’-AAGAAAGGGGACCCAAGAAA-3’

h ALP (antisense)

5’-GTACTCTCTGCCTGCCCAAG-3’

m OC (sense)

5’-TGGTGCACACCTAGCAGACAC-3’

m OC (antisense)

5’-CCGCGGGCTTGGCATCTGT-3’

m Ibsp (sense)

5′-CGCCACACTTTCCACACTCTC-3′

m Ibsp (antisense)

5′-CTTCCTCGTCGCTTTCCTTCAC-3′
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Alkaline phosphatase (ALP), osteocalcin (OC) and bone-sailoprotein (ibsp) mRNA levels
were determined using MMLV-Reserve Transcriptase (Invitrogen) and iQSYBR Green
Supermix (BioRad) and normalized to 18sRNA. Sequences of primers used of amplification of
these genes are mentioned in Table 3.1. Samples were run in a Biorad I-Cycler real time PCR
machine under the following conditions: 95°C-3min; 95°C-20s, 55°C-20s, 72°C-20s for 40
cycles. qRT-PCR experiments were performed at least thrice, with N=3 for each experiment, and
each sample was analyzed in duplicate. Absolute quantification method was used to quantify the
RNA levels. Representative experiments are shown.

Western blot analysis.
Femurs and tibiae were dissected from 6-8 week old male mice. Bones, void of marrow,
were snap-frozen in liquid nitrogen, weighed and ground into a powder. Powdered bone (10 mg)
samples were resuspended in 0.5 M EDTA pH 7.5, 1x protease inhibitor cocktail buffer and
extracted overnight at 4º C. Samples were centrifuged at 13,000 rpm for 30 minutes at 4º C and
supernatant, containing solubilized protein, was obtained for Western blot. Protein
concentrations were determined by the Bradford assay, and equal amounts were subjected to
Western blot analysis using rabbit anti-bovine osteonectin primary antibody (BON-1; gift of L.
Fisher, NIDCR, NIH) (1:4000), rabbit anti-β-actin primary antibody (Abcam, 1:1000), and goat
anti-rabbit-horseradish peroxidase conjugated secondary antibody (1:20,000) [215]. Bands were
visualized by chemiluminescence (Cell Signaling) and relative band densities were determined
using Image J software. Bands for osteonectin and β-actin were observed at 37 and 42 kDa
respectively. Expression of osteonectin was normalized to β-actin. Bones from 4 mice were used
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for each experiment, and data was obtained from 3 independent experiments. Pooled data are
shown.

Osteoblast differentiation, mineralization and proliferation analysis.
BMSCs were harvested from femurs and tibiae of 6-8 week old ONA/A and ONB/B male
mice and cultured for 6 days in media containing α-MEM and 10% FBS. For osteoblast
differentiation cultured cells were re-plated at 275,000 cells/well in a 6-well plate, grown to
confluence and differentiated for 2weeks. Differentiation was accomplished in the presence of 5
mM β-GP and 50 µg/ml ascorbic acid; and media was changed every 3 days. Cells was harvested
at 1 and 2 weeks of differentiation and processed for RNA. For assessing mineralization,
cultured BMSCs were re-plated at 110,000 cells/well in a 12-well plate, grown to confluence and
differentiated for 4 weeks. At confluence (week 0) and thereafter at all the differentiation time
points (weeks 1, 2, 3, and 4), cells were fixed in 3.7% formaldehyde and then stained with either
1% Alizarin red S pH 6.45 (Sigma) or 0.05% Crystal violet stain (Fisher Scientific). Alizarin red
stain was extracted using 10% acetic acid and 10% ammonium hydroxide, and absorbance was
quantified at 405nm. Crystal violet stain was extracted using methanol and measured at 570 nm.
For proliferation assay, cultured BMSCs were re-plated at 10,000 cells/well density in a 96-well
plate in media containing DMEM and 10% FBS. Cell proliferation was assessed over a period of
4 days using MTS CellTiter 96® AQueous One Solution cell proliferation assay kit (Promega,
Madison, USA), according to the manufacturer’s instructions. The number of metabolically
active live cells was quantified at 490nm. Representative experiments are shown.
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In vitro PTH treatment.
The effect of PTH on miR-433 expression was examined in vitro. BMSCs harvested from
6-8 weeks old C57/BL6 mice were cultured for 6 days in media containing α-MEM and 10%
FBS. Cells were re-plated at 275,000 cells/well in a 6-well plate and grown to confluence.
Confluent cultures were treated with 10 ng/ml rhPTH (1-34) (Bachem Torrance, CA) or vehicle
alone (0.1% BSA in α-MEM) for 24 hours. Cells were harvested at 3, 6, 12 and 24 hours of
treatment and processed for RNA.

To study bone-anabolic response, 10-week old male mice were injected subcutaneously
with 40 µg/kg/day rhPTH (1–34) (PTH) (Bachem, Torrance, CA) or vehicle alone (2% heatinactivated mouse serum in acidified saline), 5 days per week for 4 weeks. Mice received
intraperitoneal injections of calcien (10 mg/kg) 10 and 3 days prior to euthanasia. Femurs were
dissected and fixed in 70% ethanol [208]. All procedures were approved by the Animal Care
Committee of the University of Connecticut Health Center.

MicroCT.
Cortical and trabecular morphometry was measured in femora within the mid-diaphysis
and distal metaphysis, respectively, using conebeam micro-focus X-ray computed tomography
(µCT40, Scanco Medical AG, Bassersdorf, Switzerland). Serial tomographic volumes were
acquired at 55 kV and 145 µA, collecting 1000 projections per rotation at 300 µsec integration
time. Three-dimensional 16-bit grayscale images were reconstructed using standard convolution
back-projection algorithms with Shepp and Logan filtering, and rendered within a 12.3 mm field
of view at a discrete density of 578,704 voxels/mm3 (isometric 12-µm voxels). Segmentation of
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bone from marrow and soft tissue was performed in conjunction with a constrained Gaussian
filter to reduce noise, applying hydroxyapatite-equivalent density thresholds of 740 mg/cm3 and
500 mg/cm3 for the cortical and trabecular compartments, respectively. Volumetric regions for
trabecular analysis were selected within the endosteal borders to include the secondary spongiosa
of femoral metaphyses located 960 µm ( 6% of length) from the growth plate and extending 1
mm proximally. Trabecular morphometry was characterized by measuring the bone volume
fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular
spacing (Tb.Sp). Cortical morphometry was quantified within a 600 µm mid-diaphyseal span (50
serial sections) extending distally from the diaphyseal mid-point between proximal and distal
growth plates. Cross-sectional measurements included average total (Ta. Ar. Or sub-periosteal)
area, marrow area (Ma.Ar.), cortical area (Ct. Ar.) [216, 217].

Histomorphometry.
Undecalcified femurs were embedded in methyl methacrylate. 5 µm thick longitudinal
sections were cut on a microtome (Polycut S, Leika Heidelberg, Germany) and stained with
toluidine blue (pH 6.4). Static parameters of bone structure, formation and resorption were
measured at the distal metaphyses (magnification 400x), 195 µm from the growth plate, in a total
of 20 fields using an OsteoMeasure morphometry system (Osteometrics, Atlanta, USA).
Dynamic bone parameters were obtained from unstained 10 µm sections examined by
fluorescent light microscopy (Nikon, Tokyo, Japan). The mineral apposition rate was expressed
in micrometers per day, and bone formation rate was expressed per unit of bone surface. The
terminology and units used are those recommended by the Histomorphometry Nomenclature
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Committee of the American Society for Bone and Mineral Research [217]. 4-6 mice per group
were analyzed.

Statistics.
All the quantitative data are expressed as a mean ± SEM. Statistical significance was
determined by one-way ANOVA with Bonferroni post-hoc test or Student’s t-test.

Results

SNP 1599 modulates osteonectin 3’ UTR function and represses haplotype A 3’ UTR.
To determine the role of SNP 1599 in regulating the osteonectin 3’ UTR, we cloned the 1
kb osteonectin 3’ UTR, representing human haplotype A or B, into a Luciferase reporter
construct. In these reporter constructs, the cloned sequence functioned as 3’ UTR for the
Luciferase gene, the transcription of which was constitutively driven by a strong promoter. The
constructs were transiently transfected into hFOB1.19 cells, a conditionally immortalized human
osteoblastic cell line. We found that the haplotype A 3’ UTR construct had lower luciferase
activity compared to haplotype B, suggesting that haplotype A, which was found at a higher
frequency in the most severely affected osteoporosis patients, had a more repressive effect on
gene expression (Figure 3.1B). These data indicate that SNP 1599 contributed to differences in
osteonectin 3’ UTR function.
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Figure 3.1. Osteonectin 3’ UTR SNP 1599 regulates 3’ UTR function (A) Schematic
representation of the human osteonectin cDNA, and the characterized SNPs at bases
1046, 1599 and 1970 (grey triangles). (B) Human ON 3’ UTR (cDNA bases 1018-2123)
representing haplotypes A and B were cloned into pMIR-REPORT Luciferase vector.
Luciferase activity was quantified in hFOB1.19 cells and normalized to β-galactosidase
activity (*p<0.05 different from vector; # p<0.05 different from haplotype A, N=6).

SNP 1599 introduces a novel miR-433 binding site in haplotype A 3’ UTR.
To determine whether miRNAs may mediate the differential regulation of osteonectin by
SNP 1599G/C, we used RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/bibi/Tools.html) and
miRbase v15.0 to assemble a panel of candidate miRNAs with the potential to interact with the
region containing SNP 1599 [218]. The list of candidate miRNAs was further refined, based on
whether or not SNP 1599 would facilitate or disrupt the interaction of the miRNA with the
osteonectin 3’ UTR. We observed the potential for differential interaction of miR-433-3p, miR493-5p and miR-374a-3p in presence of 1599G (haplotype A), compared with 1599C (haplotype
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B) (Table 3.2). Moreover, these miRNAs are expressed in hFOB1.19 cells. To test the hypothesis
that the candidate miRNAs may differentially target haplotypes A and B in vitro, hFOB1.19 cells
were transiently co-transfected with either haplotype A or B 3’ UTR reporter constructs and
inhibitor for miR-433-3p, miR-493-5p or miR-374a-3p. In the presence of miR-433 inhibitor,
luciferase activity of the haplotype A construct was significantly increased compared to the nontargeting control, whereas activity of the haplotype B construct was not affected. In contrast,
inhibitor for miR-374a-3p or miR-493-5p did not significantly increase luciferase expression
from either haplotype A or B constructs (Figure 3.2A and Table 3.2).

Table 3.2. RNAhybrid analysis of putative miR-433, -493 and -374 binding sites in
osteonectin 3’ UTR. SNP 1599 G/C is indicated by underlined and larger font in the seed
binding region of haplotype A or B 3’ UTR.
miRNA!
433!

Haplotype A – SNP1599G
target 5’A

GAAAGAUUCU

374a3p

miRNA 3’UC
target 5’

A

miRNA

A 3’

GGGGCU U UUAUGA
CCUCGG GUAGUACU
A 5’
GGG
U
A 3’

AUU
GAAAG
CUUUC

miRNA 3’ UUA
target 5’

G

G

ACUGA
UGGCU
4935p!

Haplotype B – SNP1599C

CU
GA

G

GCUGU
UAUGA
UGGUAC AUGUU

G
C G

5’
C

G

A 3’

target 5’A

miRNA 3’UC
target 5’ C
miRNA

miRNA

GU
GGGGCU
CCUCGG

C

AAAG

C

A 3’

UUAUGA
AGUACU

GU
U 3’
UGAGAG
AUU UG GC
ACUUUC
UGG AC UG
3’ UU
GGA
U A
UU 5’

target 5’

U GGG UGU UUAUGA
A UCC ACAUAAUAUU
3’ GUGAAU G
A
5’

GAAAGAUUCU
ACUGA
UGGCU

A 5’

GG

C

C G
C
A 3’
U GGG UGU UUAUGA
A UCC ACA AAUAUU
3’ GUGAAU G
A
U
5’

miR-433 targeting of haplotype A 3’ UTR was also evaluated in hFOB1.19 cells using
miR-433 mimic and a scramble mimic control. In the presence of miR-433 mimic, haplotype A
3’ UTR luciferase activity was inhibited compared to the control, whereas haplotype B 3’ UTR
activity was not significantly affected (Figure 3.2B). These results suggest that SNP 1599
introduces a novel miR-433 binding site in haplotype A 3’ UTR, which may contribute to
differential regulation of osteonectin. However, our data do not preclude the possibility that other
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miRNAs or trans-acting factors could also demonstrate differential regulation of the
haplotype A and B 3’ UTRs.

Figure 3.2. miR-433 represses haplotype A 3’ UTR, and miR-433 decreases during
osteoblastic differentiation, and inhibits differentiation . (A) Luciferase activity of
haplotype A and B-3’UTR pMIR-report constructs in hFOB1.19 cells co-transfected with
specific miRNA inhibitors or scramble control. Inhibitors for miR-433, -493 and -374a
(A) and miR-433 mimic or scramble control mimic (B) were tested; luciferase activity
was normalized to β-galactosidase activity (* p<0.05 different from scramble control,
N=6). (C) miR-433, alkaline phosphatase (ALP) and osteocalcin (OC) RNA in hFOB
1.19 cells at confluence (0), and during osteoblastic differentiation. miR-433 normalized
to RNU48; ALP and OC mRNA normalized to 18s RNA (*p<0.05 different from
confluence, N=3). (D) ALP and OC RNA in hFOB1.19 cells transfected with miR-433 or
scramble inhibitor and cultured in osteoblast differentiation medium for 3 days (*p<0.05
different from scramble inhibitor, N=3).
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miR-433 expression decreases during osteoblastic differentiation.
Since miR-433 could differentially regulate the human osteonectin 3’ UTR, we
determined whether the expression of this miRNA was altered during osteoblastic differentiation,
using hFOB1.19 cells as a model [212, 213]. Osteoblastic differentiation was induced using a
vitamin D-containing cocktail, and after 3 or 6 days, mRNAs for the early osteoblastic marker
alkaline phosphatase (ALP), and the mature osteoblast marker, osteocalcin (OC), were
dramatically increased. In contrast, expression of miR-433 decreased during differentiation, such
that miR-433 levels were lowest when osteoblastic differentiation markers were highest (Figure
3.2C). A similar phenomenon was reported by others when miR-433 levels were evaluated in a
BMP2-treated murine pre-osteoblast cell line [191]. To determine the role of miR-433 in human
osteoblastic differentiation, hFOB1.19 cells were transfected with either a miR-433 inhibitor or a
scramble control inhibitor and subjected to osteoblastic differentiation for 3 days. Here, miR-433
inhibitor increased mRNA for the osteoblast markers ALP and OC, compared to the scramble
control, confirming that miR-433 is a negative regulator of osteoblast maturation in vitro (Figure
3.2D).

SNP 1599 affects osteonectin expression in vivo.
Many mature miRNAs display sequence conservation across species, and the sequence of
mature miR-433 is identical between mouse and human (miRBase). Whereas selected regions of
the mouse and human osteonectin 3’ UTR are highly conserved, such as the miR-29 binding sites
in the proximal portion of the UTR [219], mouse and human osteonectin are not well conserved
in the region containing human SNP1599 (UCSD Genome Browser). Therefore, to examine the
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impact of SNP 1599 on osteonectin expression in bone in vivo, we used a knock-in strategy to
replace the mouse osteonectin 3’ UTR with the 1 kb human osteonectin 3’ UTR, representing
either haplotype A (ONA/A) or haplotype B (ONB/B) (Figure 3.3A). In relation to other mouse
strains, C57Bl/6 mice have a low bone mass phenotype [220, 221].

Figure 3.3: Osteonectin protein levels are higher in bone of haplotype B knock-in mice.
(A) Schematics shows the strategy for generating haplotype A and B knock-in mice, mouse
genome region from exon 10 and a part of intron 9 was replaced with a human osteonectin 3’
UTR. (B) Osteonectin mRNA and (D) miR-433 levels was quantified by qRT-PCR using
RNA isolated from the femurs of 6-8 week old ONA/A and ONB/B mice. Osteonectin mRNA
levels were normalized to 18s RNA, miR-433 levels were normalized to sno202 RNA; (N=4
mice/ haplotype, * p<0.05 different from haplotype A). (C) Western blotting for osteonectin
and β-actin in lysates from long bones of ONA/A and ONB/B mice (*p<0.05 different from
haplotype B, N=3 mice/group).

We chose to examine the function of the human osteonectin 3’ UTR haplotypes in the
C57Bl/6 genetic background because our candidate gene study revealed an association between
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osteonectin haplotype and bone mass only in the idiopathic osteoporosis patient group. We
reasoned that the effect of the osteonectin 3’ UTR haplotype might be most apparent in a low
bone mass background, where other gene variants may not be sufficient to rescue a low bone
mass phenotype. Moreover, we chose to limit our present analysis to males, to further mimic our
previous study in male idiopathic osteoporosis patients.

Osteonectin transcript and protein levels in femur of homozygous haplotype A and B
(ONA/A and ONB/B) male mice were examined. Western blot analysis of protein extracts
demonstrated 2-3 fold lower osteonectin levels in ONA/A femur in comparison to ONB/B,
indicating that SNP 1599 contributed to differential osteonectin accumulation in bone in vivo
(Figure 3.3C). At the same time, qRT-PCR revealed a ~2 fold increase in osteonectin mRNA in
femur of ONA/A mice compared with ONB/B (Figure 3.3B), while miR-433 levels were similar
(Figure 3.3D). This apparent discrepancy may be related to the fact that the protein data
represent the accumulation of osteonectin in bone tissue, whereas the RNA data represent a
window of gene expression at 6-8 weeks of age. SNP 1599 affects changes in bone mass with
age.
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Figure 3.4. Gain in trabecular bone is higher in haplotype B knock-in mice. µCT analysis
of changes in femoral bone from 10 to 20 weeks of age in ONA/A and ONB/B mice. (A)
Changes in trabecular and (B) cortical bone compartments are shown. Trabecular bone volume
(BVF), trabecular bone number (Tb.N) trabecular bone spacing (Tb.Sp.). Total (periosteal)
area (Tt.Ar), marrow area (Ma.Ar), cortical area (Ct.Ar). *p<0.05 different from haplotype A,
N=4-9 mice/group. (C) Representative µCT images from femora of 20 week old mice.

Using µCT, we analyzed the skeletal phenotype of male ONA/A and ONB/B mice at 10 and
20 weeks of age. The femurs of 10-week old mice ONA/A and ONB/B displayed similar trabecular
and cortical bone parameters (Table 3.3). At 20 weeks of age, trabecular bone volume and
trabecular thickness were significantly higher in ONB/B mice compared with ONA/A (Table 3.3).
When the percentage change in trabecular bone parameters between 10 and 20 weeks was
examined, the differences between the two genotypes became more apparent (Figure 3.4A and
C). For example, between 10 and 20 weeks of age, ONB/B mice realized a 20-25% gain in
trabecular bone volume fraction (BVF), while ONA/A mice did not. Trabecular number (Tb.N)
decreased with age in both the genotypes, and the decrease was significantly less in ONB/B mice.
Trabecular spacing (Tb.Sp.) increased between 10 and 20 weeks of age in ONA/A mice, but not in
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ONB/B animals (Figure 3.4A and C).

In contrast, cortical bone area (Ct.Ar.) increased from 10 to 20 weeks of age in both
genotypes, to a similar extent (Figure 3.4B and C). This was not unexpected, as the osteonectinnull and haploinsufficient mice display primarily defects in trabecular bone volume [208].
Overall, these data suggest that human osteonectin 3’ UTR haplotypes A and B differentially
affect the trabecular bone compartment, and that ONB/B gained more trabecular bone with age
than ONA/A mice.
Table 3.3. µCT analysis of trabecular and cortical bone parameters in femur of 10week and 20-week old male ONA/A and ONB/B mice. Trabecular bone volume fraction
(BVF), trabecular bone number (Tb.N) trabecular bone spacing (Tb.Sp.) and trabecular
thickness (Tb.Th.). Total (periosteal) area (Tt.Ar.), marrow area (Ma.Ar.), cortical area
(Ct.Ar.); (10 weeks; N = 4-5 mice per group, 20 weeks; N = 8-9 mice per group) *p<0.05
different from haplotype A.
Trabecular

AA
10 weeks

20 weeks

10 weeks

20 weeks

BVF (%)

12.60±0.01

12.20±0.00

11.70±0.02

14.80±0.01*

Tb.Th.(µm)

45.48±3.72

46.97±1.23

53.06±2.76

55.24±1.89*

Tb.N.(/mm)

5.20±0.33

4.20±0.18

4.47±0.30

4.23±0.14

Tb.Sp.(µm)

192.25±11.97

237.56±9.59

225.06±17.56

232.34±9.46

Cortical

AA

BB

10 weeks

20 weeks

10 weeks

20 weeks

Tt.Ar.(mm )

1.96±0.10

2.24±0.04

1.89±0.03

2.062±0.11

2

1.08±0.04

1.24±0.02

1.00±0.03

2

0.88±0.06

0.96±0.03

0.88±0.02

2

Ma.Ar.(mm )
Ct.Ar.(mm )
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1.08±0.08
0.98±0.04

SNP 1599 modifies the bone anabolic effect of intermittent PTH.
Since intermittent administration of PTH is the best bone anabolic therapy currently
available, we studied the response of ONA/A and ONB/B mice to this treatment. 10-week old male
mice were injected daily with 40 µg/kg PTH (1-34) or vehicle, 5 days per week, for 4 weeks.
µCT analysis showed that after 4 weeks of treatment, PTH significantly increased cortical bone
area in both ONA/A and ONB/B mice, however the gain in cortical bone in ONB/B mice was nearly
twice than that observed in ONA/A mice (Figure 3.5B and C, Table 3.4).

Figure 3.5: PTH induced gain of cortical bone area is greater in haplotype B knock-in
mice. µCT analysis of femoral trabecular bone from 14-week old ONA/A and ONB/B mice that
had been injected for 4 weeks with 40 µg/kg/day PTH or vehicle. (A) Percent change in
trabecular bone parameters vs. vehicle in femur. (B) Percent change in cortical bone
parameters vs. vehicle in femur. Trabecular bone volume (BVF), trabecular thickness
(Tb.Th), trabecular bone number (Tb.N) Total (periosteal) area (Tt.Ar), marrow area (Ma.Ar),
cortical area (Ct.Ar). (C) µCT images of femoral bones of vehicle and PTH treated ONA/A and
ONB/B mice.
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The PTH mediated increase in the total cross-sectional area (Tt.Ar.) was greater in ONB/B
mice compared with ONA/A mice, providing a mechanism for increased cortical bone area. PTH
mediated changes in marrow area (Ma.Ar.) did not reach significance (p=0.07) in either genotype
(Figure 3.5B and C and Table 3.4). These data indicate that the bone anabolic effect of
intermittent PTH was greater in ONB/B mice compared to ONA/A. We also assessed changes in the
trabecular bone at the femoral metaphysis of PTH or vehicle injected mice using microCT.
Although the PTH-mediated increase in trabecular bone volume was not statistically significant,
PTH did increase trabecular thickness and number to a similar extent in mice of both genotypes
(Figure 3.5A, Table 3.4).
Table 3.4. µCT analyses of trabecular and cortical bone parameters in femur of vehicle
and PTH injected ONA/A and ONB/B mice. 14-week old haplotype A and B knock-in mice that
had been injected for 4 weeks with 40 µg/kg/day PTH or vehicle. Trabecular bone volume
fraction (BVF), trabecular bone number (Tb.N) trabecular bone spacing (Tb.Sp.) and trabecular
number (Tb.N.). Total (periosteal) area (Tt.Ar.), marrow area (Ma.Ar.), cortical area (Ct. Ar.).
(N=4-6 mice per group) # p<0.05 different from corresponding vehicle injected mice of the
same genotype. Data is represented as mean ± SEM.
Trabecular

AA
Vehicle

PTH

Vehicle

PTH

BVF (%)

12.00±0.01

14.00±0.01

12.00±0.01

16.00±0.01

Tb.Th.(µm)

47.03±1.16

59.54±1.94

#

46.40±2.54

61.65±3.81

Tb.N.(/mm)

4.43±0.04

4.10±0.16

#

4.72±0.16

4.25±0.21

Cortical

AA
PTH

Vehicle

Tt.Ar. (mm )

2.15±0.07

2.17±0.08

2.00±0.05

2

1.22±0.06

1.15±0.05

1.10±0.03

2

0.93±0.02

Ma.Ar. (mm )
Ct.Ar. (mm )

#

BB

Vehicle
2

!

BB

1.02±0.02
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#

0.90±0.02

PTH
2.36±0.06

#

1.21±0.07
1.09±0.02

#

Histomorphometry was used to evaluate bone remodeling parameters and bone formation
rate in femoral trabecular region of vehicle and PTH injected ONA/A and ONB/B mice [217].
Interestingly, osteoblast number was lower in vehicle treated ONB/B mice compared to ONA/A,
whereas bone formation rate (BFR) was higher in the vehicle treated ONB/B mice (Figure 3.6;
Table 3.5). These data suggest greater bone forming activity, per cell, in ONB/B mice. With PTH
treatment, osteoblast number and bone formation rate in both ONA/A and ONB/B mice were
significantly increased, such that they were equivalent. Differences in osteoclast number and
eroded surface were not seen between ONA/A and ONB/B mice, in the presence or absence of PTH
treatment (Table 3.5).

Altogether, these data indicate that ONA/A mice have decreased bone formation
compared with ONB/B mice, providing an explanation for the failure of ONA/A mice to increase
trabecular bone volume from 10 to 20 weeks of age (Figure 3.4, Figure 3.6; Table 3.5).
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To determine whether PTH might have a direct effect on miR-433 expression, wild type mouse
BMSCs were cultured to confluence, serum-deprived, and treated with PTH or vehicle for 3, 6,
12 or 24 hours of treatment (Figure 3.7D). However, PTH treatment did not regulate miR-433
levels at any time point tested, suggesting that the actions of PTH on bone in vivo may not be
related to direct effects on miR-433.

Table 3.5 Histomorphometric analysis of femoral trabecular bone of vehicle and PTH
injected ONA/A and ONB/B mice. 14-week old haplotype A and B knock-in mice that had
been injected for 4 weeks with 40 µg/kg/day PTH or vehicle (N = 4-6 mice per group) #
p<0.05 different from the corresponding vehicle injected mice of the same genotype. *
p<0.05 different from haplotype A mice in the same treatment group. Data is represented as
mean + SEM.
AA

Histomorphometry

BB

Formation

Vehicle

PTH

Osteoblast number
2
(N.Ob/B.Pm, /mm )
Mineralizing surface
(MS/BS, %)
Bone formation rate
3
2
(µm /µm / day)

1.64±0.26

6.28±1.16

4.77±0.55

10.58±1.63

93.29±1.17

317.27±35.02

#

#

#

Vehicle

PTH

0.91±0.23*

6.39±1.52

7.34±0.90*

8.86±1.16

168.36±21.90*

196.81±21.34

AA

!

#

BB

Resorption

Vehicle

PTH

Vehicle

PTH

Osteoclast number
2
(N.Oc/B.Pm; /mm )
Osteoclast surface
(Oc.S/BS, %)
Eroded surface
(ES/BS, %)

0.91±0.22

0.81±0.25

0.72±0.07

0.80±0.21

2.54±0.64

2.27±0.66

1.97±0.21

2.26±0.10

5.67±1.14

5.63±1.05

4.76±0.53

5.29±0.38
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Figure 3.6: Bone formation rate is greater in haplotype B knock-in mice.
Histomorphometric analysis of femoral trabecular bone from 14-week old ONA/A and
ONB/B mice that had been injected for 4 weeks with 40 µg/kg/day PTH or vehicle. (A)
Osteoblast number and (C) bone formation rate in femoral trabecular bones of vehicle and
PTH treated ONA/A and ONB/B mice (*p<0.05 different from ONA/A mice, N=4-6/group).
Red arrows indicate (B) toluidine blue stained osteoblasts and (D) calcien double labels.
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Cell autonomous effect of SNP 1599 on osteoblastic differentiation and mineralized matrix
deposition.
To determine whether the effect of SNP 1599 on bone formation was cell autonomous,
we monitored osteoblastic differentiation markers in BMSCs from ONA/A and ONB/B mice
cultured for up to 2 weeks. After 1 week of culture in osteoblast differentiation medium, ONB/B
cells displayed significantly more osteocalcin and bone sialoprotein mRNA compared to ONA/A
cultures (Figure 3.7E and F). After 2 weeks of culture, bone sialoprotein mRNA levels were no
longer significantly different between genotypes, whereas osteocalcin mRNA remained elevated
in ONB/B cultures. We also assessed mineralized matrix deposition in BMSCs undergoing
osteoblastic differentiation in vitro. Mineralized matrix deposition was quantified using alizarin
red staining, whereas differences in cell density were monitored by crystal violet staining. The
stains were then solubilized and quantified; and alizarin red staining was normalized to crystal
violet (Figure 3.7 A and B). Although both cultures were plated at the same density, crystal
violet staining was greater in ONA/A compared to ONB/B cultures (Figure 3.7 B). Crystal violet
staining peaked at week 2 in ONA/A cultures, and at week 3 in ONB/B cultures. However, despite
the lower cell number, ONB/B cultures showed a greater alizarin red staining at weeks 3 and 4 of
differentiation. After normalizing alizarin red staining by crystal violet, the difference in
mineralized matrix deposition between ONA/A and ONB/B cultures became more apparent. This
suggests that ONB/B osteoblasts deposited significantly more mineralized matrix per cell
compared to ONA/A cultures, and support the in vivo observations (Figure 3.7A and B).
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Figure 3.7. Osteoblast mineralization and differentiation capacity is higher in haplotype
B mice. (A, B) Quantified alizarin red stain normalized to crystal violet in differentiated
BMSCs from ONA/A and ONB/B mice indicate increased osteoblast mineralization/per cell
equivalent in ONB/B. (C) Growth of ONA/A and ONB/B BMSCs over 4 days of culture was
assessed by MTS assay read at 490nm, (N = 6/ time point/assay/group). (D) Confluent BMSC
cultures of C57/BL6 mice were treated with 10ng/ml PTH for 24 hours, miR-433 levels were
quantified and normalized to sno202 RNA by qRT-PCR (N=3-4, data points are represented
as mean ± SEM). (E) Osteocalcin and (F) Bone sailoprotein RNA in BMSCs from ONA/A and
ONB/B mice undergoing osteoblastic differentiation for 2 weeks (*p<0.05 different from
haplotype A, N=3). (*p<0.05 different from haplotype A, N = 4).

To determine whether there were inherent differences in the growth rate of ONA/A and
ONB/B BMSCs, MTS assay was used to monitor the growth of sub-confluent cultures. We found
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that the growth rate for ONA/A and ONB/B stromal cells did not differ (Figure 3.7C). Similarly,
previous in vitro studies showed that osteonectin-null osteoblasts displayed decreased osteoblast
maturation and mineralized matrix deposition, but no defects in cell growth [189]. The present in
vitro studies support the concept that, in BMSCs, osteonectin levels do not impact cell growth,
but have effects on osteoblastic differentiation.

Discussion

Skeletal phenotype is a complex genomic trait, and only a minute fraction of the genetic
variants contributing to this phenotype have been identified. Further, the in vivo function of most
osteoporosis associated polymorphisms identified through GWAS and candidate gene studies is
not known [200]. In this study, we developed a novel knock-in mouse model to determine the in
vivo impact of a human regulatory region polymorphism on skeletal phenotype. This model
demonstrated that a SNP in the osteonectin 3’ UTR can regulate osteonectin levels and bone
volume, essentially validating the association between osteonectin 3’ UTR SNP haplotypes and
bone mass first identified in a cohort of Caucasian men with idiopathic osteoporosis [186].
Moreover, we identified a potential molecular mechanism by which this SNP regulates
osteonectin expression, through differential targeting of a miRNA (Figure 3.8).
Bone matrix is enriched in osteonectin. This integrin-binding matricellular protein is
important for regulating collagen matrix assembly and organization [222-224]. In fact, many
connective tissue pathologies detected in osteonectin-null mice have been attributed to defective
extracellular matrix composition [223-225]. In vitro and in vivo studies demonstrate that
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collagen fibril organization is impaired in bone matrices of osteonectin-null mice, likely
contributing to decreased bone mineralization [223]. In vitro, osteonectin promotes osteoblast
survival, differentiation and matrix mineralization [189]. It is possible that extracellular matrix
organization differs between ONA/A and ONB/B mice, which may contribute to differences in
osteoblastic differentiation and mineralization; studies to address these questions are ongoing.
Although we did not analyze osteonectin mRNA or protein levels in ONA/A and ONB/B mice after
PTH administration, studies by Turner et al. (2007) showed that intermittent PTH administration
increased osteonectin mRNA in bone of rats subjected to hind limb unloading [226].

Figure 3.8. Working model for osteonectin 3’ UTR SNP mediated effect on bone. In
haplotype A knock-in mice, osteonectin levels in bone are lower compared to haplotype B
knock-in mice. The osteonectin 3’ UTR haplotype A is targeted by miRNA (miR-433),
which may contribute to lower osteonectin and lower bone volume.

Previously, we reported that although osteonectin-null and haploinsufficient mice gain
bone in response to intermittent PTH therapy, their bone-anabolic response was less than that
seen in wild type mice. For the most part, the response of these mice to PTH could be related to
osteonectin gene dosage [208]. Although the dose of PTH used in our previous study was higher
than the one used in this report (80 vs. 40 µg/kg/day), our results suggest that higher levels of
osteonectin in bone are associated with greater PTH-mediated bone gain, particularly with regard
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to the cortical compartment (Figure 3.5B). It is possible that the higher levels of osteonectin in
ONB/B mice could facilitate the anabolic response of bone to intermittent PTH treatment.

The expression of osteonectin is tightly regulated through mechanisms that alter
transcription, mRNA stability, and translation [219, 227-232]. In osteoblasts, the osteonectin
transcript is quite stable, with a half-life of >24 hours under conditions of transcription arrest
[232]. Therefore, regulation of translation would likely provide the most rapid means of
decreasing osteonectin synthesis. Recently, 2 evolutionarily conserved binding sites for the miR29 family of miRNAs were found in the proximal region of the osteonectin 3’ UTR [219].
Induction of miR-29 expression by canonical Wnt signaling provided potent repression of
osteonectin protein synthesis, within one hour of treatment [219]. This example illustrates the
efficiency by which miRNAs could regulate osteonectin levels.

In this study, we identified miR-433 as a miRNA that could play a role in regulating
osteonectin expression. The mature miR-433 sequence is identical between mice and humans,
and the organization of the miR-433 genomic locus conserved. Previously, miR-433 was shown
to decrease during BMP2- induced osteoblastic differentiation of C3H10T1/2 cells, and to target
the Runx2 3’ UTR [191]. Our study confirms that miR-433 expression decreases during
osteoblastic differentiation in human cells, and that miR-433 has an inhibitory effect on
differentiation (Figure 3.2). We also demonstrated that SNP 1599 modulates the ability of miR433 to regulate the human osteonectin 3’ UTR (Figure 3.2). Although the effect of the miR-433
inhibitor on the haplotype A construct was modest, it is consistent with effects reported in other
studies, and may reflect the relatively low level of miR-433 expression in the human osteoblast
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cell line [212]. Moreover, osteonectin is expressed in multiple tissues, many of which likely have
a complement of miRNAs that are distinct from that found in the bone cells. Other miRNAs
might bind to the osteonectin 3’ UTR, and differential binding of these miRNAs to the region
containing SNP 1599 must be strongly considered.

Table 3.6. Osteonectin SNP 1599 (rs1054204) allele and genotype frequencies (from
dbSNP summary for ss68954048).
Population ID

Ethnicity

Allele Frequency

HapMap-CEU

European

C=0.533
G=0.467

HapMap-JPT

Asian

C=0.522
G=0.478

HapMap-YRI

Sub Saharan
African

C=0.742
G=0.258

Genotype Frequency
C/G=0.433
C/C=0.317
G/G=0.250
C/G=0.511
C/C=0.267
G/G=0.222
C/G=0.567
C/C=0.350
G/G=0.083

Others have examined the potential association of osteonectin SNPs with disease
phenotype in systemic sclerosis, hepatocellular carcinoma, glaucoma, and keratoconus [233237]. Although some studies have associated particular osteonectin 3’ UTR SNPs and disease,
these reports have not involved SNP 1599, nor have they described potential mechanisms.
Osteonectin SNP 1599G is a common variant (Table 3.6) [238]. In a sample population of North
Americans that are of African descent, frequency of the SNP1599G allele, present in haplotype
A, is less than that for populations of European or Chinese descent (dbSNP summary for
ss68954048). Studies have shown that, as a group, African Americans have higher bone mineral
density compared to Caucasians [239, 240]. Although several candidate genes have been
associated with BMD within these groups, it is not clear whether decreased frequency of SNP
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1599G could play a part in this effect [241].

In the literature, there has been argument about whether the majority of phenotypic
variance is driven by rare variants with large effects or by common variants with small effects
[242]. Most likely, rare and common variants work together, in conjunction with geneenvironment interactions, to specify phenotype. The present study was performed in an inbred
mouse strain, and the animals were housed in well-controlled environmental conditions. These
experimental parameters allowed us to decrease the impact of genetic variance and geneenvironment interactions on trabecular and cortical bone phenotype. This permitted us to assign a
physiological function to a common osteonectin allele, providing support for its contribution to
the complex trait of skeletal phenotype.

Presently, estimation of a patient’s risk of fracture is performed using models based on
clinical, demographic and anthropomorphic information, such as BMD, previous fracture, a
parent with hip fracture, smoking, glucocorticoid and alcohol use. Although valuable, the
prognostic performance of these models could be improved especially in case of idiopathic
osteoporosis. Including genetic profiling data for an individual could help improve accuracy of
risk assessment and better inform treatment decisions [243]. Osteonectin SNP 1599 could be of
importance to consider in investigations of idiopathic osteoporosis. However, the impact of a
single variant on fracture risk is small, and identification of many more gene variants with an
impact on the skeleton is necessary before real gains in fracture prediction can be realized [243,
244]. Data such as those reported here will contribute to the pool of SNP variants needed for
individualized risk assessment and fracture prevention.
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CHAPTER 4
Function of miR-365, -99b and -451 in osteoclasts
Portions of this chapter have been published in:
Pathway analysis of microRNA expression profile during murine osteoclastogenesis
Tiziana Franceschetti, M.S.*1, Neha S. Dole, M.S.*1, Catherine B. Kessler, B.S.1, Sun-Kyeong
Lee, Ph.D.2, and Anne M. Delany, Ph.D.1
* These authors contributed equally to the work.

Abstract
Osteoclast formation and function are tightly regulated by transcriptional, posttranscriptional and post-translational mechanisms. This stringent control is critical to prevent
excessive or insufficient bone resorption and to maintain normal bone homeostasis. microRNAs
(miRNAs) are key post-transcriptional regulators that repress expression of target mRNAs
controlling osteoclast proliferation, differentiation, and apoptosis. With the goal of designing
novel therapeutics for bone loss, it is critical to define the function of individual miRNAs in the
osteoclast lineage.

Our previous miRNA expression profiling studies suggest that miRNAs-99b, -365 and 451 are dramatically regulated during the RANKL-driven osteoclastic differentiation of an
enriched population of murine bone marrow osteoclast precursors. Here, we validated these
miRNA expression data and demonstrate that miR-99b is crucial for osteoclast differentiation. In
contrast, miR-365 appears to be a negative regulator of osteoclast formation, but a positive
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regulator of overall osteoclast size. Computational analyses predicted mTOR, PI3 kinase/AKT,
and Calcium signaling pathways to be top targets of miR-99b and -365 in osteoclasts. To identify
miRNA targets in an unbiased manner, miRNAs and their targets are frequently coimmunoprecipitated with the RISC complex. We also optimized a RISC immunoprecipitation
protocol for osteoblastic and osteoclastic cells. Overall, our study is unique in that we identified
function of 2 miRNAs that are induced during osteoclastogenesis, and we report an optimized
strategy for RISC-RNA immunoprecipitation in bone cells.

Introduction

Bone mass is a well-known determinant of bone strength, and reflects the net outcome of
bone formation and resorption. Maintenance of healthy bone mass requires tight regulation on
the number and activity of bone forming osteoblasts and bone resorbing osteoclasts. Imbalance
in bone remodeling, with accelerated bone resorption, can result in bone loss, as that observed in
post-menopausal osteoporosis patients. Novel therapeutic interventions to reduce such
osteoclast-mediated bone loss require understanding of the molecular mechanisms regulating
osteoclast formation and activity.

Osteoclastogenesis is an intricate process that involves the differentiation of common
myeloid progenitors to monocyte precursors, commitment of these precursors to the osteoclast
lineage, followed by the migration and fusion of osteoclast precursors into multinucleated
polykaryons [9]. The two major cytokines essential and sufficient to induce osteoclastogenesis
are macrophage-colony stimulating factor (M-CSF, CSF1) and receptor activator of nuclear
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factor kappa-B ligand [7]. The is former required for proliferation and survival of osteoclast
precursors, while the later is needed to drive osteoclastogenesis [41].

Osteoclast differentiation is regulated by transcriptional and post-transcriptional
mechanisms. Transcription factors essential for osteoclastogenesis, including PU.1, MITF
(microphtalmia associated transcription factor), and c-Fos are activated upon differentiation of
the mutlipotent common myeloid progenitors, to mediate commitment of monocytic precursors
to osteoclast lineage. PU.1 drives differentiation of monocytic precursors towards the osteoclast
and macrophage lineage [245-247]. This was essentially demonstrated by the lack of osteoclasts
and macrophages in PU.1-/- mice, although these mice contained functional monocytes. In
conjunction with MITF, PU.1 drives expression of osteoclast genes such as RANK, Cathepsin K
(Ctsk), tartrate resistant acid phosphatase 5 (TRAP/Acp5), osteoclast-associated receptor
(Oscar), osteopetrosis-associated transmembrane protein 1(Ostm1) and Chloride channel 7
(Clcn7) [34, 40, 42, 248, 249].

In addition to promoting their osteoclastic commitment, c-Fos prevents commitment of
monocytic precursors to the dendritic lineage [33]. Although c-Fos-/- mice contain macrophages,
they lack osteoclasts, indicating that c-Fos functions downstream of PU.1 in the transcription
program of osteoclast commitment. c-Fos is also necessary for upregulation of RANK
expression in pre-osteoclasts upon M-CSF signaling [250-252]. Following osteoclast
commitment, RANKL signaling induces NFATc1 (nuclear factor of activated T-cells)
expression. NFATc1 functions as a master transcriptional regulator, driving osteoclastic
differentiation of mononuclear osteoclast precursors into polykaryonic mature osteoclasts that
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resorb bone [253]. RANKL activates NFATc1 through two pathways: calcium-calmodulin
signaling and by activating NF-κB, which directly binds to NFATc1 promoter [35, 252, 254].
Interestingly, NFATc1 complexes with other transcription factors including PU.1, MITF, NF-κB
and c-Fos, to induce expression of osteoclast genes such as Ctsk, Oscar, TRAP and Calcitonin
receptor [40-42].

In addition to regulation at the level of transcription, post-transcriptional mechanisms
also play fundamental role in osteoclastogenesis, and miRNAs are critical post-transcriptional
regulators of gene expression. The importance of miRNAs in osteoclast biology was initially
demonstrated by 2 studies that deleted a key miRNA-processing enzyme, Dicer, in cells of the
osteoclast lineage. Dicer deletion mediated by a CD11b-Cre transgene abrogated miRNA
biogenesis in the monocytic cells that give rise to osteoclasts. CD11b-Dicer-/- mice developed
osteopetrosis, due to decreased osteoclastogenesis and bone resorption [255]. Moreover,
Cathepsin K-Dicer-/- mice also developed mild osteopetrosis, due to impaired miRNA biogenesis
in mature osteoclasts [46]. Subsequently, the function of only a few miRNAs in osteoclasts has
been revealed. For example, overexpression of miR-155 was shown to block osteoclastogenesis,
and downregulate MITF expression. Being highly expressed in macrophages, the negative role of
miR-155 in osteoclasts suggests that it promotes commitment of monocytic precursors to the
macrophage lineage, at the expense of osteoclastogenesis [256-258]. In contrast, the PU.1
transcription factor was shown to induce expression of miR-223 during osteoclastogenesis, and
inhibition of miR-223 decreases osteoclast formation. The positive role of miR-233 in
osteoclasts was illustrated by its targeting of the NFIA (nuclear factor I-A) gene, a transcription
factor that suppresses MCSF mediated signaling in osteoclasts [255, 259, 260].
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Although the overall importance of miRNAs in the osteoclast lineage is recognized, there
is little information about the function of specific miRNAs in osteoclasts [104, 174, 255, 258,
259, 261, 262]. In human genome, although there are a limited number of miRNAs, their effect
is substantial, as a single miRNA may regulate hundreds of genes. Indeed, > 30% of protein
coding genes are estimated to be targeted by miRNAs [87]. This makes it difficult to predict the
effects a single miRNA might have on cell phenotype. For designing miRNA-based therapeutics
for pathologies caused by excessive or insufficient osteoclast activity, a thorough understanding
of the function of specific miRNAs and their panel of target genes will be necessary.

Recently, a microarray study in RAW264.7 cells (murine monocyte cell line)
documented a panel of miRNAs that were up or down regulated during osteoclastic
differentiation [263]. Information on miRNAs expressed during differentiation of primary bone
marrow cells into osteoclasts was, however, still lacking. Moreover, osteoclast formation, which
begins with mononuclear cells and ends with polykaryons, is quite a dramatic cellular
metamorphosis and it is likely that the miRNA expression profile may differ at every stage of
osteoclastogenesis. Thus, it is crucial to examine miRNAs expressed at different stages of
osteoclast formation and not just at the endpoints of the process.

Therefore, we profiled miRNAs expressed during the early, middle and late stages of
osteoclastogenesis in an enriched osteoclast progenitor population from murine bone marrow.
The resulting data set was unique in that it was derived from a primary cell population with
decreased heterogeneity, and it revealed miRNAs expressed during different stages of
osteoclastogenesis, providing a better insight on the role of miRNAs in this process.
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Cluster analysis of these data revealed panels of miRNAs expressed during early, middle
and late stages of osteoclastogenesis. Of note, miR-365-3p and miR-99 family members
(consisting of miR-99a, -99b and -100) were strongly up regulated during osteoclastogenesis.
[263]. Presently, there is not much was known about these miRNAs. The goal of our study was
to investigate the function of these miRNAs in osteoclast differentiation, and to identify some
potential target genes in osteoclasts.

We validated that expression of miR-365-3p, -99b-5p and -451 during osteoclastogenesis
in a population of primary murine bone marrow cells enriched for osteoclast progenitors, as well
as in RAW264.7 cells. Through gain and loss of function studies, we determined their role in
osteoclast differentiation. Our computational predictions of miR-365-3p and -99b-5p targets and
their pathway analysis suggest potential molecular mechanisms involved. Lastly, in an effort to
design an unbiased approach to identify miRNA target genes, we optimized an Ago-RNAimmunoprecipitation protocol for osteoblastic and osteoclastic cells. In summary, our approach
provides an outline of fundamental methodology that can be utilized for studying miRNA
function in osteoclasts.

Materials and Methods

Ethics statement.
All animal protocols were approved by the Institutional Animal Care and Use Committee
at the University of Connecticut Health Center (protocol 100435-0315).
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Cell culture.
Primary osteoclast precursor cultures were established using bone marrow from 6-8 week
old C57BL/6 male mice, which had been enriched for osteoclast precursors by depletion of
B220/CD45R-positive and CD3-positive cells (B and T lymphocytes, respectively). Briefly,
bone marrow was isolated from femurs, tibias, and humeri, and depleted of erythrocytes by
treatment with ammonium-chloride-potassium (ACK) buffer (Gibco Life Technologies, Grand
Island, NY) [264]. Cells were incubated with Phycoerythrin (PE)-conjugated primary antibodies
for CD45R and CD3 (eBioscience, San Diego, CA), and with magnetically labeled anti-PE
microbeads (MiltenyiBiotec, Auburn, CA). Magnetic-Activated Cell Sorting (MACS®) Column
Technology (MiltenyiBiotec, Auburn, CA) was used to capture CD45R and CD3 positive cells in
the column, and the flow-through contained a population of cells enriched for monocytic and
non-lymphoid lineage cells.

Cells were cultured in α-MEM (Gibco Life Technologies, Grand Island, NY)
supplemented with 10% FBS (Fetal Bovine Serum, Atlas Biologicals, Fort Collins, CO) and 30
ng/ml murine recombinant Macrophage Colony-Stimulating Factor (M-CSF) (eBioscience, San
Diego, CA). Bone marrow-derived osteoclast precursor cells were cultured in the presence of 30
ng/ml M-CSF and 30 ng/ml murine recombinant RANKL (eBioscience) for up to 5 days.

RNA-immunoprecipitation studies were performed in the human fetal osteoblastic
hFOB1.19 cell line (CRL-11372) and the mouse monocytic RAW264.7 cell line (TIB-71TM),
purchased from American Type Culture Collection. hFOB1.19 cells were grown at 33.5ºC in
DMEM/ F12 media (Gibco Life technologies, Grand Island, NY) supplemented with 10% FBS
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(Lonza, BioWhittaker

TM

) and 1% penicillin/ streptomycin. RAW264.7 cells were cultured in

DMEM (Gibco Life technologies, Grand Island, NY) supplemented with 10% FBS (Atlas
Biologicals, Fort Collins, CO) and 1% penicillin/streptomycin. For osteoclastic differentiation,
RAW264.7 cells were cultured in 30 ng/ml RANKL.

In Vitro Osteoclast Formation Assay
Cells were fixed with 2.5% glutaraldehyde in PBS, and TRAP activity was detected
according to the manufacturer’s instructions using the Acid Phosphatase Leukocyte (TRAP) kit
(Sigma-Aldrich). Osteoclast cultures were imaged using light microscopy and TRAP positive
cells with more than 3 nuclei were counted as osteoclasts. CellSens Dimension software
(Olympus) was used to measure osteoclast area. N=6. Data shown are representative of 2
independent experiments.

Quantitative Real time PCR
miRNA expression levels were analyzed using the TaqMan MicroRNA Assay (Life
Technologies, Grand Island, NY). According to the manufacturer’s instructions, 22.5 ng of RNA
were reverse transcribed with specific primers to generate cDNA. The expression of miR-3653p, miR-99b-5p, and miR-451 was detected by qPCR in a MiQ qPCR cycler (Bio-Rad). miRNA
levels were normalized to U6 small nuclear RNA (RNUB6) levels, using the absolute
quantification method. Data are presented as mean ± SEM. Data were analyzed by one-way
ANOVA with Bonferroni post-hoc test, as appropriate (KaleidaGraph, Synergy Software,
Reading, PA).
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Inhibitor or mimic transfection and osteoclastogenesis
Bone stromal cells (BMSCs) isolated from long bones of 6–8-week-old C57BL/6 mice
were cultured overnight to reduce the amount of stromal cells. Enrichment in monocyte
precursor population was achieved by subjecting the non-adherent cells to density gradient
centrifugation with Ficoll (GE Healthcare, Piscataway, NJ). Bone marrow-derived monocytes
(BMMs) were plated at 30,000 cells/well in 96-well plates and cultured in α-MEM supplemented
with 10% FBS (Atlas) in the presence of 10 ng/ml M-CSF for two days. Subsequently, cells were
transfected with anti-miRNA inhibitors or miRNA mimics (Dharmacon) or non-targeting
controls at 50 nM concentration using HiPerFect transfection reagent (Qiagen, Valencia, CA). 6
hours post-transfection, osteoclast differentiation was induced with M-CSF (30 ng/ml) and
RANKL treatment (30 ng/ml), and osteoclast formation was evaluated by TRAP staining.

RNA Immunoprecipitation (RNA-IP)
We performed RNA-IP in hFOB1.19 and RAW264.7 cell lines, to optimize the
technique for osteoblast and osteoclast lineage cells. To determine if the technique can be
efficient to immunoprecipitate RISC-associated RNAs, we chose to examine levels of miR-29
family members (a and c), as they are expressed in both lineages. Cells were grown to
confluence, harvested by scraping in ice cold PBS (5ml/ plate), and washed in PBS (5ml/ plate, 2
washes). For hFOBs 15-20 x 106 cells (corresponding to 5-7 10 cm plates, ~3x106 cells/ plate),
and for RAW264.7 2 x 106 cells (corresponding to 1 10 cm plate, ~10x106 cells / plate) were
used for preparing cell lysates. Cells were incubated in polysome lysis buffer (275 ul for
hFOB1.19 or 600 ul for RAW264.7 cells) [PLB composition- 100 mM KCl, 5 mM MgCl2, 10
mM HEPES, pH7.0, 0.5% NP-40, 1 mM DTT, 400 uM Vanadyl ribonucleoside complexes
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(VRC), protease inhibitor cocktail (1x- HaltTM , Thermo Scientific)] for 10 minutes on ice, and
homogenized (5 passes through a 21G gauge needle with a 1 ml syringe). Protein G Dynabeads
(Invitrogen) were rinsed and blocked with 1 mg/ml BSA and 0.5 mg/ml yeast tRNA (50 ul of
beads with 450 ul of blocking solution) for 30 minutes. Following the initial blocking step, beads
were incubated with 5 ug of monoclonal anti-AGO (2A8) or IgG antibody (Millipore) in PBS for
2 hours (200 ul). Beads were then washed in lysis buffer (25 mM Tris-HCl at pH 8.0, 150 mM
NaCl, 2 mM MgCl2, 0.5% NP-40 and 5 mM DTT). Cell lysate was clarified by centrifugation at
13,000 rpm for 30 minutes (4 ºC), added to anti-Ago or IgG labeled beads, and incubated from 4
hours at 4 ºC. We found that overnight incubation of cell lysates with the antibody leads to
protein degradation. After co-IP, stringency was achieved by sequential washes: beads were
washed twice in lysis buffer containing 900 mM NaCl, 1% NP-40 and twice again in lysis buffer
with 0.05% NP-40. Subsequently, beads were resuspended in buffer (40 mM Tris-HCl at pH 8.0,
10 mM MgSO4, 1 mM CaCl2, 200 U/ml RNasin) and aliquots were used for RNA and protein
analysis. RNA was harvested using Qiazol and analyzed by qRT-PCR. Aliquots of lysate were
mixed with an equal volume of 2X Lamelli sample buffer (62.5 mM Tris-HCl pH 6.8, 25%
glycerol, 2% SDS, 0.01% bromophenol blue) and subjected to Western blot analysis [265, 266].
We were able to isolate ~250 ng of RNA from the immunoprecipitated complexes in hFOB 1.19
cells (15 x 106 cells) and ~850 ng of RNA from RAW264.7 cells (1.7 x 106 cells).

Western blot analysis
Equal volume of lysates in 2X Lamelli sample buffer prepared from hFOB1.19 cells (15
x106 cells) were analyzed by Western blot. AGO immunoprecipitation was confirmed by
immunoblotting for Anti-pan Ago, clone 2A8 primary antibody (Millipore 1:1000) and goat anti-
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mouse IgG- horseradish peroxidase conjugated secondary antibody (1:10,000). Bands were
visualized by chemiluminescence (Cell Signaling) and relative band densities were determined
using Image J software. The band for AGO protein was detected at ~95 kDa. The antibody has
been reported to cross react with radixin, as shown by the band at ~70 kDa.

Results

Differential miRNA expression during in vitro osteoclastogenesis.
Although mouse bone marrow is a widely used source of primary osteoclast progenitors
for in vitro analyses, it represents a highly heterogeneous population, containing monocytes,
megakaryocyte precursors, macrophages, neutrophils, and higher percentages of lymphocytes.
Flow cytometric analysis suggests that, after erythrocyte depletion, 25-30% of total bone marrow
is B220+ and 5-7% is CD3+ (unpublished data, personal communication from Dr. SK Lee). Prior
studies indicate that the B220-/CD3-/CD11b-/lo population in the bone marrow constitutes the
fraction of osteoclast precursors that have the highest potency for osteoclast formation [267,
268]. We sought to decrease the heterogeneity in primary osteoclast precursor population before
initiating osteoclastogenesis, by depleting the lymphocytic cells. Therefore, mouse bone marrow
cells were subjected to MACS sorting using CD45R and CD3 antibodies. We cultured mouse
bone marrow-derived osteoclast precursors in the presence of M-CSF and RANKL for up to 5
days. At days 1, 3, and 5 of culture, total RNA was harvested. Osteoclast differentiation was
examined by TRAP staining, and we reported elsewhere a progressive increase in the expression
of the osteoclast markers TRAP and Cathepsin K during this time [262].
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Profiling expression of miRNAs during osteoclastogenesis.
Our miRNA microarray analysis showed that miR-99b levels increased by ~4.5 fold and
miR-365 levels increased by ~ 11 fold from day 1 to day 5 of osteoclastogenesis. In contrast,
miR-451 levels dropped ~30 fold by day 3 and were almost undetectable by day 5 of osteoclast
differentiation [138]. Expression and function of these selected miRNAs had not been previously
reported in the osteoclast lineage. We verified the results of our microarray using quantitative
RT-PCR (qRT-PCR) and confirmed changes in the levels of miRNAs during differentiation. We
observed that both miR-365-3p and miR-99b-5p expression progressively increased with
osteoclast formation (Figures 4.1 A). Both miR-365-3p and miR-99b are well expressed and
showed ~12 fold robust upregulation after 5 days of osteoclastogenesis.

Figure 4.1. Expression profile of miR-99b-5p, miR-365-3p and miR-451 during
osteoclastogenesis. Murine bone marrow cells depleted of the CD45R+ and CD3+ population
were differentiated with 30 ng/ml M-CSF and RANKL for up to 5 days. Expression of miR99b-5p, miR-365-3p (A) and miR-451 (B) was quantified and normalized to U6 RNA, n=4,
*p<0.01 different from day 1. (C) Expression of miR-365-3p and miR-99b-5p in cells cultured
for 3 days in 30 ng/ml M-SCF, and either in presence or absence of RANKL (30 ng/ml),
miRNA levels were and normalized to U6 RNA, n=4, *p<0.01 different from M-CSF group.
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In contrast, miR-451 expression dramatically decreased from day 1 to day 3, and was
nearly undetectable day 5 of osteoclast differentiation (Figure 4.1 B). Differences in the fold
changes detected by microarray and the qRT-PCR are attributed to sensitivity of the assays.
qRT-PCR assay provides a wider dynamic range for miRNA detection compared to the
microarray platform.

We then compared miRNA expression in cultures differentiated with and without
RANKL for 3 days. qRT-PCR showed that at day 3, both miR-365 and miR-99b levels were ~4
fold higher in RANKL treated cultures compared to those grown in its absence. (Figure 4.1 C).
miR-451 expression was not detected in the day 3 cultures treated with or without RANKL,
thereby suggesting that the decrease in miR-451 levels during osteoclastogenesis was
independent of RANKL (data not shown). It is likely that the high levels of miR-451 detected at
day 1 in primary cultures is due to the heterogeneous mix of cells in our culture.

We further examined expression of the selected miRNAs during differentiation of
RAW264.7 cells (murine monocytic cell line). RAW264.7 cells were cultured in the presence of
RANKL for up to 4 days, to induce osteoclastogenesis. Total RNA was harvested at days 0, 1, 2,
3, and 4 of RANKL treatment. Expression of miR-451 was not detectable in RAW264.7 cells
(data not shown). Although we detected miR-99b expression in RAW264.7 cells, there was no
change in its levels during osteoclastic differentiation (Figure 4.2 A). miR-365 levels
progressively increased, such that they were ~ 2.5 fold higher after 4 days of osteoclastogenesis
in the RAW264.7 cells (Figure 4.2 B).
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Likewise, another group performing miRNA microarray analysis in RAW264.7 cells
treated with TNFα and RANKL showed an increase in miR-365 after 82 hours of treatment,
whereas changes in miR-99b levels were not documented in that study [263].
!

Figure 4.2. Expression of miRNAs in RAW264.7 cells stimulated with RANKL.
RAW264. 7 cells were differentiated for up to 4 days into osteoclast with 30 ng/ml
RANKL. Expression of miR-99b-5p (A) and miR-365-3p (B) was quantified and
normalized to U6 RNA by qRT-PCR, n=4, *p<0.01 different from day 0.

Examining the role of candidate miRNAs in osteoclastogenesis
To determine whether the strongly up-regulated miRNAs had a positive role in
osteoclastogenesis, bone marrow-derived monocytes (BMMs) were transiently transfected with
inhibitors for miR-99b-5p or miR-365-3p. Osteoclast number and size were determined after 3
days of culture in the presence of RANKL. Inhibition of miR-99b activity resulted in a 50%
decrease in osteoclast number compared to the control inhibitor, and the osteoclast size was also
significantly reduced (Figure 4.3 A, B and C). This decline in osteoclast number and size
indicates that miR-99b is crucial for osteoclast formation.
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In contrast to miR-99b, inhibition of miR-365 increased osteoclast number, while
decreasing osteoclast size. These data suggest that miR-365 may fine tune osteoclastogenesis,
regulating osteoclast size and number in an opposing manner. In other cell types, miR-365 has
been shown to target Cyclin D1 and CDC25A, as well as pro-apoptotic BAX [269, 270]. Thus,
inhibition of miR-365 activity could lead to increased cell number, a potential explanation for the
increased osteoclast number observed in our studies (Figure 4.3 A, and C). The increased levels
of miR-365 during osteoclast differentiation could slow proliferation and increase survival.

Since miR-451 levels were dramatically decreased during osteoclast differentiation, to
test its function, BMMs were transfected with a miR-451 mimic prior to RANKL-mediated
differentiation. However, osteoclast number and size were not affected by the miR-451 mimic,
suggesting that this miRNA may not have a significant role in osteoclastogenesis in vitro,
although these data do not preclude potential actions in vivo (Figure 3.2 D and E). Several
reports have revealed that miR-451 expression is required for erythroid differentiation and
homeostasis [271, 272]. It is possible that the high levels of miR-451 observed in cultured
osteoclast progenitors could reflect the presence of erythroid precursors.
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Figure 4.3. Function of miR-99b, -365 and -451 in osteoclasts. Primary BMMs were
transfected with 50 nM miRNA inhibitors (A and B) or miRNA mimic (D and E) or the
appropriate non-targeting control. Cells were differentiated into osteoclasts with treatment
of M-CSF and RANKL (30 ng/ml each) for 3 days. Osteoclast formation was evaluated by
TRAP staining. Osteoclast number and size, *p<0.05 different from control inhibitor
(n=6). (C) Representative images of miR-99b, -365 and control inhibitor transfected
osteoclasts (4x magnification).

!

94!

Analysis of pathways targeted by miRNAs during osteoclastogenesis
Since a single miRNA can potentially target hundreds of genes, deciphering the role of
miRNAs by identifying target genes can become cumbersome. However, miRNAs frequently
target mRNAs important in a common signaling pathway. Therefore, some strategies for trying
to refine lists of potential miRNA targets include pathway analysis. We used this bioinformatics
approach in an attempt to understand to potential pathways and target genes regulated by our
selected panel of miRNAs. MicroRNA target recognition, for most part, is thought to be
nucleated by complementarity between the miRNA seed region and the mRNA target, and this
forms the basis for many miRNA computational prediction algorithms designed. In addition to
seed binding, secondary structure and complementarity in non-seed regions, as well as
evolutionary conservation can also be taken into consideration for target prediction. The 3’ UTR
tends to be enriched for miRNA binding sites. Thus, many earlier computational strategies
limited analysis to the 3’ UTR of genes. More recently developed algorithms scan for miRNAseed sequences in the 5’ UTR and coding sequence (CDS), in addition to the 3’ UTR.

We performed miRNA binding site prediction for miR-99b and miR-365 using three
different

computational

prediction

algorithms:

DIANA-microT-CDS

(v5.0)

(http://www.microrna.gr/microT-CDS), miRanda! (http://www.microrna.org/microrna/home.do)
and TargetScan (http://www.targetscan.org/mmu_61/), in an attempt to achieve higher accuracy
in target gene prediction [273-275]. We did not analyze potential targets for miR-451, since it
does not appear to have an impact on osteoclastogenesis in vitro. Our analysis revealed 72 genes
predicted as miR-99b targets by all three algorithms, while 1324 genes were predicted as miR365 targets (Figure 4.4 A and 4.4 B). Using DIANA-miRPath (v2.0 software) we performed a
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KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis that enabled us to predict
global pathways that may be potentially regulated by a specified set of miRNAs. This algorithm
retrieves potential miRNA targets genes from TargetScan, Pictar and DIANA-microT-CDS
programs and fits them into all available KEGG pathways. The efficiency of miRNA-mRNA
seed interaction and the number of predicted target genes are combined to calculate a P-value, to
suggest potential pathways that might be regulated by the miRNA.

Figure 4.4. Pathway prediction analysis for miR-99b and miR-365. Computational
prediction databases, DIANA-microT-CDS, TargetScan and miRanda together predicted
(A) 72 common genes as miR-99b targets and (B) 1324 common genes as miR-365
targets. (C) Heat map of predicted pathways targeted by these miRNAs. Red color
indicates lower p values.
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Combined DIANA-miRPath analysis predicted heparin sulfate/heparin, prostate cancer,
and mTOR signaling pathways are most likely to be targeted by miR-99b, whereas mTOR,
gliomas and biosynthesis of unsaturated fatty acids are the top predicted pathways most likely to
be targeted by miR-365 (Figure 4.4 C). Because the mTor pathway was predicted to be enriched
for both miR-99b and miR-365 targets, this pathway was examined further (Figure 4.5).
Predicted miR-99b targets in the mTOR pathway were mTor and the fg1r (insulin growth factor
1 receptor) (Table 4.1). Predicted miR-365 target genes regulating signaling in the mTOR
pathway were Rheb (Ras homolog enriched in brain), p110 α subunit of PI3K
(phosphotidylinositol-3 kinase catalytic subunit), and Ifg1 (insulin growth factor) (Table 4.2).
The importance of mTOR signaling in osteoclastogenesis has been previously demonstrated. In
osteoclasts, M-CSF signaling is crucial for osteoclast survival; this effect is mediated through
mTOR. mTOR downregulates expression of Bim, a pro apoptotic gene and promotes osteoclast
survival [276-278]. Moreover, recent studies demonstrated that inhibition of mTOR led to
reduction in osteoclast formation and resorption [279-281].

miR-99b has been shown to directly target and downregulate mTOR and Akt1, thereby
affecting mTOR/Akt/PI3K signaling pathway critical to mediate most cellular responses
including proliferation, migration and survival [276-278]. miR-99b has been identified as a
tumor suppressor in several cancer studies due to its role in regulating cell proliferation and
migration. That the miRPath software detected miRNA-target interactions have already been
validated reflects the promise of this approach.
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Figure 4.5. DIANA-miRPath prediction target analysis showed genes potentially
regulated by miR-99b-5p and miR-365-3p in mTOR signaling.

Type I IGF receptor (IGF1R), predicated to be a miR-99b target, (Table 4.1) was recently
validated as a miR-99b target [140]. In bone, IGF1 receptors are expressed by osteoblasts,
osteocytes and osteoclasts. A positive role of IGF1/IGF1R signaling in promoting osteoblast
commitment, differentiation and function has been previously demonstrated. Moreover, global
deficiency of IGF1 decreases osteoclastogenesis by impairing the interaction of osteoclast
precursors with osteoblasts [282, 283]. However, to definitely deduce the function of IGF1
signaling in osteoclasts, generating an osteoclast specific IGF1R deletion using CD11b or
Cathepsin K-Cre mouse model would be necessary.
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Table 4.1 Predicted binding sites for miR-99b-5p in the 3’ UTR of target genes
using miRanda computation database!
!

!

Rheb (Ras homolog enriched in brain) was predicted to be a miR-365 target. It belongs
to the Ras superfamily of GTPases, and activates mTOR to regulate energy metabolism in cells.
Nutrient deprivation decreases mTOR activity, to reduce energy-associated activities like cell
growth, and prolonged nutrient deficiency comprises cell survival [284]. Rheb has been shown to
be able to rescue mTOR function in nutrient starved conditions, thereby indicating its importance
in promoting cell survival and growth [285]. Global deficiency of Rheb leads to embryonic
lethality with abrogation of multiple organ development [286]; in bone however, the function of
Rheb has not been examined.

PI3K is a major signaling pathway activated by M-CSF and RANKL during
osteoclastogenesis and it promotes osteoclast differentiation, motility and bone resorption [287,
288]. PI3K are classified as type IA and IB, and there are three catalytic subunits for class IA
PI3K, including p110−α (encoded by Pik3ca), p110-β (encoded by Pik3cb), and p110-δ
(encoded by Pik3cd). Catalytic subunits bind to one of the regulatory subunits, such as p85−α
and its splicing variants p55−α and p50−α (encoded by Pik3r1). miR-365 is predicted to target

!

99!

p110 α catalytic subunit. In osteoclasts, p110−α has been recognized as the more dominant PI3K
subunit and in vitro inhibition of p110- α isoform-mediated signaling of PI3K directly inhibits
osteoclastogenesis and bone resorption in vitro [289]. Global deficiency of p110-α leads to
embryonic lethality, and although the impairment in bone resorption due to deficiency of p85−α
regulatory subunit specifically in osteoclasts (Ctsk-Cre) has been demonstrated, the function of
p110- α has not been validated in vivo [288, 290]. Using these computational tools, both genes
and pathways targeted by miR-99b and miR-365 in osteoclasts can be predicted, to provide a
rationale for the selection of potential targets and pathways to be validated experimentally.

Table 4.2 Potential binding site for miR-365-3p in the 3’UTR of target genes
using miRanda computation database!
!

miR$365$3p)target)genes)
3' uauuccuaaaaauccCCGUAAu 5' mmu-miR-365
||||||
1156:5' aacuuauuuaaacuuGGCAUUu 3' Pi3kca)

!

mirSVR)Score)
)

-0.0618

3' uauUCCUAAAAAUCCCCGUAAu 5' mmu-miR-365
| || ||||| ||||||
248:5' accAAGAAUUUUAUCGGCAUUa 3' Rheb

-0.6501

3' uauuccuaaaaaUCCCCGUAAu 5' mmu-miR-365
| |||||||
144:5' aacauuacaaagAUGGGCAUUu 3' Igf1

-0.8632
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RNA immunoprecipitation
Although the bioinformatic tools can provide a vast pool of potential target genes for a
specific miRNA, these target predictions are based on a certain set of assumptions, and there is
still much we do not know about miRNA-target interactions. With the goal of providing an
experimental, unbiased, high throughput approach for detecting miRNA target genes, RNAimmunoprecipitation techniques have been developed. These techniques exploit the RISCmiRNA-mRNA interaction, and RNA sequencing or microarray analysis. Together with
bioinformatic analysis, this approach can provide enrichment in miRNA target genes and insight
into the regulatory pathways that might be impacted by a test miRNA [291-293].
The technique is frequently performed by over expressing the test miRNA in cells,
followed by pulldown of RISC proteins, which leads to the capture of test miRNA-enriched
target genes. RISC proteins are frequently immunoprecipitated using an antibody against the
essential RISC component, AGO. As an alternative, cells can also be transfected with a construct
expressing a tagged RISC protein (i.e. c-myc-tag, 6x-histidine-tag, biotin-tag), allowing RISC
immunoprecipitation using antibody against the tag [294].
mRNAs bound to immunoprecipitated RISC are then analyzed by a high throughput
approach

such

as

microarray,

in

a

process

termed

RIP-ChIP

(ribonucleoprotein

immunoprecipitation followed by microarray chip analysis) or sequencing termed RIP-Seq
(ribonucleoprotein immunoprecipitation followed by high-throughput sequencing). Comparison
of RISC-bound mRNA targets in cells overexpressing a miRNA versus a control miRNA
provides the panel of mRNAs that may be potentially enriched in the miRNA targets. Based on
the previously established approaches for RISC pull down, we sought to optimize an AGO pull
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down technique as a first step for identification of miRNA targets in osteoblast and osteoclast
lineage cells. Since different AGO (1-4) proteins vary in their preference for binding miRNAs
and have different efficacies [85, 295], we chose to use 2A8 anti-AGO antibody for RISC
immunoprecipitation [296]. This antibody recognizes all four AGO proteins from mouse and
human, making it applicable for miRNA pull down in RAW264.7 cells (derived from a mouse
source) and hFOB 1.19 cells (derived from a human source). Initial immunoprecipitation of
RISC was performed in hFOB1.19 cells using 2A8 antibody, and as a negative control, a nonimmune IgG was used. Protein samples were prepared from total cell lysate (input), lysate that
was bound to anti-AGO or IgG, and the unbound material from immunoprecipitation.
Immunoblotting indicated presence of AGO (band corresponding to ~95kDa) in total cell lysate
and the lysate fraction bound to anti-AGO. With 2A8-immunoprecipitation, ~7 fold more AGO
protein was captured compared to the total cell lysate. A band at ~70 kDa, corresponding to the
actin binding protein Radixin was also detected due to its cross reaction with 2A8 antibody
(Figure 4.6 A). Radixin has no known role in miRNA regulation [296] and was also detected in
the total cell lysate, and the unbound fractions. Interestingly, radixin was detected in the IgG
bound lysates, but not Ago-bound.

To examine miRNA coimmunoprecipitation with AGO, we performed qRT-PCR using
RNA obtained from AGO- and IgG- pull down. In hFOB1.19 cells, qRT-PCR demonstrated that
more than ~900 fold enrichment in miR-29a was achieved through AGO-IP compared to IgG
negative control (Figure 4.6 B). We performed the same procedure in RAW264.7 cells
subsequently and showed ~ 300 fold enrichment in miR-29c using qRT-PCR (Figure 4.6 C). In
conclusion, we confirmed the consistent efficiency of our AGO immunoprecipitation and this
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optimized protocol will provide a firm foundation toward future studies aimed at identifying
miRNA targets in osteoblasts and osteoclasts, in a non-biased manner.

Figure 4.6. Argonaute coimmunoprecipitates are enriched for miRNAs. Lysates from
hFOB1.19 cells were immunoprecipitated with anti-AGO or IgG (negative control) antibody.
Immunoblotting for AGO in hFOB1.19 cells, samples include input: total lysate, Ago-, IgGunbound and bound proteins (A). AGO1-4 band (~70-95kDa) (asterisk); radixin cross-reactive
band (~70kDa) (arrow). RNA samples obtained from hFOB1.19, input: total lysate RNA, IgGand AGO- bound RNA and AGO- bound RNA. Transcript levels of miR-29a were quantified
and normalized to RNU48 endogenous control (B). RNA samples obtained from RAW264.7
cells, input: total lysate RNA, IgG- and AGO- bound RNA and AGO- bound RNA. Transcript
levels of miR-29c were quantified and normalized to U6 endogenous control (C).

Discussion

To summarize our findings, we showed that, in a population of primary murine bone
marrow cells enriched for osteoclast progenitors, RANKL mediated osteoclastogenesis increased
miR-99b and -365 levels, while miR-451 levels were down regulated. We demonstrated that in
the down regulation of miR-99b impaired osteoclast differentiation, leading to reduced osteoclast
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number and size. Our computational pathway predictions suggest that the positive role of miR99b might involve fine-tuning of NF-κB signaling. In contrast, miR-365 was shown to negatively
regulate osteoclastogenesis. Computational predictions suggest that both miR-99b and miR-365
may target genes important for mTOR signaling, which is crucial for osteoclast formation and
apoptosis. With the goal of designing an unbiased approach to identify miRNA target genes, we
optimized an AGO immunoprecipitation technique, to pull down miR-RISC-mRNA complexes
for analysis in osteoblasts and osteoclasts.

miR-99b is transcribed in an evolutionary conserved cluster on mouse chromosome 17,
which includes let-7e and miR-125a. All of which were significantly upregulated during
osteoclastogenesis, as reported by our microarray data and by others [138, 140]. miR-99b
belongs to miR-99 family that includes miR-99a and -100. Both miR-99a and -99b have a similar
seed sequence, except for a single nucleotide difference, suggesting that they likely target the
same genes. Interestingly, in our microarray, expression of miR-99a and miR-100 were also up
regulated during osteoclastogenesis.

A recent study confirmed our findings about the positive role of miR-99b in human
osteoclasts, and identified a NF-κB binding site near the transcription start site (TSS) of the miR99b~let-7e~miR-125a cluster [140]. Chromatin immunoprecipitation demonstrated increased
binding of p65 NF-κB to this region during osteoclast differentiation, providing a mechanism for
the upregulation of miR-99b during osteoclastogenesis. Remarkably, their study also showed
significant upregulation of miR-99b cluster in immature osteoclasts compared to macrophages
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and dendritic cells, thereby indicating that this cluster might act as a regulatory switch for
osteoclast commitment [140].
miRNA-99b is also upregulated in dendritic cells and monocytes during inflammation
[299]. Furthermore, miR-99b was shown to directly target Tnfα, Tnfrsf4 (Tumor Necrosis Factor
Receptor Superfamily, Member 4), and TRAF2 (TNF receptor-associated factor 2), in other cell
types. This implies regulation of the TNFα (tumor necrosis factor α) signaling pathway, which
promotes osteoclastogenesis [297, 299].

Figure 4.7. Potential working model for miR-99b role in osteoclastogenesis. miR-99b
in osteoclasts may be potentially involved in fine-tuning of NF- κB signaling to promote
osteoclast formation. miR-99b may potentially inhibit NF-κB expression by targeting
TRAF2 gene [297]. While miR-99b induced SMAD3 phosphorylation leads to NF-κB
activation through SMAD3/TRAF6 interaction [298].

NF-κB promotes miR-99b

expression in osteoclasts [140].

During osteoclastic differentiation, membrane bound RANK mediates its signal
transduction through TRAFs, to activate a series of downstream cascades including NF-κB,
PI3K/Akt, p38/JNK and calcium/calmodulin pathways [37-39]. Together, these pathways
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regulate cell proliferation, migration, differentiation and survival. miR-99b has been also shown
to promote SMAD3 phosphorylation in cells of mouse mammary gland [298]. Interestingly,
SMAD3 promotes osteoclast formation, and interacts with TRAF6-TAB1-TAK1 molecular
complex [300]. In osteoclasts, upon RANKL stimulation, TRAF6 is recruited to form a complex
with TAK1 (TGF-beta activated kinase 1, MAPKKK family member) and activate PI3K,
MAPKs and NF-κB pathways [301]. This indicates that the upregulation in miR-99b during
osteoclastogenesis may play a role in fine-tuning NF- κB signaling [28, 250]. Since inhibition of
miR-99b decreased osteoclast differentiation, it is likely that the appropriate balance between
these signaling pathways is important for the differentiation process.

Figure 4.8. Potential working model for miR-365 inhibition of osteoclastogenesis.
Negative role of miR-365 may likely involve inhibition of PI3 Kinase and mTOR
signaling. Predicted miR-365 targets relevant in these signaling mechanisms include
PI3K, Rheb, and IGF1R.

miR-365 is transcribed from two independent genetic loci (miR-365-2 on mouse
chromosomes 11 and miR-365-1 on chromosome 16), that give rise to the identical mature
miRNA and expression of miR-365-1 was shown to be activated by Sp1 and NF-κB, two
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transcription factors that promote osteoclastogenesis [302]. In osteoclasts, we showed miR-365
to negatively regulate osteoclast differentiation. Our computational predictions suggest that miR365 may regulate key signaling pathways in osteoclasts including mTOR and PI3K signaling. In
osteoclasts, PI3K/ Akt and mTOR pathways coordinated to promote osteoclast differentiation,
migration and resorption [280, 287, 303-305]. miR-365 levels likely play a role in this
coordination to promote optimal osteoblast differentiation and function.

Recently there have been some technical advancements, to improve high throughput
capture of miRNA targets. Techniques used for miRNA target capture so far include indirect and
direct approaches. The indirect approaches for Ago-RNA immunoprecipitation rely on
transfection of cells with miRNA mimics or inhibitors followed, by high throughput
transcriptome analysis through microarray or sequencing. Transcriptome analysis fails to detect
the mRNAs that are regulated primarily by translational repression. This can be overcome by
proteomic analysis following AGO pulldown. A rather cost effective alternative to proteome
analysis for miRNA targets is polysome profiling; where after miRNA overexpression, mRNAs
bound to the ribosomes are captured and profiled by deep sequencing.
To enhance the mRNA target capture, modifications have been made to RISC
immunoprecipitations, to improve the miRNA-RISC-mRNA interaction, in a technique termed
CLIP (crosslinking and immunoprecipitation). For the CLIP technique, following miRNA
overexpression, RISC proteins are U.V. (ultraviolet) cross-linked with the RNAs and
immunoprecipitated to capture mRNA targets [89, 294, 306]. CLIP is combined with high
throughput sequencing HTS-CLIP (high-throughput sequencing of CLIP- cross linking with
UVc-254nm) to identify captured miRNA targets. Modifications to HTS-CLIP have been made
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in form of PAR-CLIP (Photoactivatable ribonucleoside enhanced CLIP) technique. In PARCLIP photoreactive ribonucleoside analogues are incorporated into RNAs before their
crosslinking to protein via exposure to UVa-365nm [307-309]. However, disadvantages to the
above mentioned target identification techniques remain. For example, they cannot distinguish
between direct and indirect miRNA targets; they enable interaction of non-miRNA targets to
RISC, thereby yielding false positives; and these indirect approaches require additional
computational predictions to select direct miRNA targets for experimental validation [294].
To overcome these issues, the novel technique of miR-CLIP (microRNA crosslinking and
immunoprecipitation) was developed. In this technique, pre-miRNAs modified with psoralen and
biotin are transfected in cells for miRNA overexpression. Following photoactivatable
crosslinking of RISC protein and RNA, immunoprecipitation of both RISC and tagged miRNA is
performed. In this way, mRNA targets specific for the tagged miRNA are captured and identified
by deep sequencing, and the stringency in mRNA target capture is enhanced [310]. Using
modifications

that

enable

identification

of

physiologically

relevant

targets

without

overexpression or depletion of miRNA would be key to provide insight about miRNA regulatory
mechanisms in natural environment of transcript.
To summarize we determined the function of miR-365 and miR-99b in osteoclasts, and
used available miRNA target prediction computational tools to identify potential pathways that
might be regulated by these miRNAs. This provides a rationale for selecting potential miRNA
targets to be validated experimentally. We also optimized, in osteoclastic and osteoblastic cells,
an AGO-immunoprecipitation technique that can be utilized to identify putative miRNA targets.
!
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Chapter 5
Summary, significance and conclusions
Summary
The overall goal of this study was to understand how specific miRNAs regulate
osteoblast and osteoclast differentiation and function, and thereby skeletal phenotype.

We first determined whether miRNAs play a part in the differential regulation of
osteonectin 3’ UTR SNP haplotypes. A previous candidate gene study had associated osteonectin
3’ UTR SNP 1599 (rs1054204) with low bone mass in a cohort of idiopathic osteoporosis
patients [186]. We identified the mechanism underlying this association by generating and
analyzing knock-in mouse models for human osteonectin SNP 1599. We found that this SNP
mediated differential regulation of the osteonectin 3’ UTR, and demonstrated differential
targeting by miR-433. In vivo, SNP 1599 variants displayed differences in trabecular bone
volume and a differential response to a bone-anabolic PTH regimen. Ex vivo studies
demonstrated that SNP 1599 caused a cell autonomous alteration in osteoblast differentiation
markers and mineralized matrix deposition. Altogether, we were able to assign a function to a
common variant SNP 1599, and demonstrated that SNPs can regulate skeletal phenotype through
mechanisms involving miRNAs (Chapter 3).

With regard to miRNAs and osteoclasts, we determined functions of three novel
miRNAs, miR-99b, -365 and -451, in osteoclast differentiation. Microarray analysis previously
suggested that these miRNAs could be strongly regulated during the osteoclastic differentiation
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of progenitors derived from murine primary bone marrow monocytes [138]. We observed a
RANKL mediated upregulation in miR-99b and -365 levels during osteoclast differentiation;
whereas expression of miR-451 declined. Our in vitro studies demonstrated that miR-99b is
crucial for osteoclast differentiation; its knock down led to fewer osteoclasts. In contrast, knock
down of miR-365 led to increased osteoclast number. Lastly, modulation of miR-451 levels did
not impact osteoclastogenesis.

To start deciphering the molecular mechanisms that might be regulated by these
miRNAs during osteoclast differentiation, we performed a computational target-pathway
prediction analysis. These predictions suggested that miR-99b and miR-365 might regulate
osteoclast differentiation through fine-tuning signaling in mTOR pathway. Apart from
computational predictions, we aimed to design an unbiased, high throughput experimental
approach involving RNA immunoprecipitation, for identifying miRNA targets in osteoblasts and
osteoclasts. We optimized immunoprecipitating the AGO component of RISC complexed to
miRNA:mRNA target pairs. Through immunoblotting and qRT-PCR analysis we demonstrated
that these immunoprecipates are greatly enriched for miRNAs. Our subsequent studies will entail
designing a miRNA overexpression system and high throughput analysis, such as RNA
sequencing, to capture miR-99b and miR-365 targets in osteoclasts (Chapter 4). Through these
studies we will identify new targets of miR-99b and -365, and expand our understanding of
osteoclast biology.
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Significance
Bone mass is a heritable trait and an increasing number of GWAS have detected BMDassociated SNPs in protein coding and the non-coding genes. Currently used fracture risk
assessment models are based on clinical, demographic and anthropomorphic information such as
BMD, family history and lifestyle. The addition of genetic profiling data could greatly improve
the accuracy of such prognostic models, and potentially help inform treatment strategies.
However, for genetic profiling data to have an important impact on fracture risk assessment, the
identification of many more genetic variants with a verified function in bone mass is crucial. Our
study is unique, in that we have validated and assigned a physiological function to a common
SNP variant previously associated with bone mass in a candidate gene study.

Moreover, the SNP we validated is a non-coding gene variant and is a miRNA-associated
SNP. Our study provides evidence for implicating miRNA-associated SNPs in skeletal diseases,
and suggests miRNAs are crucial regulators of skeletal phenotype. SNP variants related to
miRNA function can be incorporated into diagnostic screens for individualized risk assessment.

Although the role of microRNAs in regulating bone development and homeostasis has
been recognized, the underlying mechanisms are not well understood, and such an understanding
is critical for designing novel clinical interventions involving miRNA-based therapeutics. Recent
studies have implicated miRNAs in the pathogenesis of osteoporosis. For example, increased
levels of five circulating miRNAs were found in the serum and bone tissue of osteoporotic
patients, suggesting a potential opportunity for using serum miRNAs as diagnostic biomarkers
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for osteoporosis [144, 311]. Current strategies for diagnosis of osteoporosis rely on BMD
measurement by DXA. Although a non-invasive, changes in BMD are small and are often
detected by DXA only at the latter stages of disease progression. Circulating miRNAs may serve
as improved biomarkers in the early stages of osteoporosis.

The majority of studies examining miRNA function in bone biology have narrowly
focused on specific miRNA targets or one regulatory mechanism at a time. As part of our
studies, we optimized the first step of a global, unbiased, high throughput approach for
identifying microRNA-target interactions in bone cells. Moreover, we also demonstrated the
utility of a pathway-based bioinformatic approach to miRNA target prediction, which could ease
interpretation of large data sets and help establish connectivity of miRNA-dependent regulatory
networks. This could facilitate building a hypothesis-driven approach to understanding the
function of miRNAs in bone cells. Moreover, knowledge from our study can be used to deduce
to function of miRNAs (miR-365, -99b and -433) in other tissues as well. In doing so, we have
provided a ‘big picture’ approach, which will be important for therapeutic intervention, to better
predict potential side effects or unintended outcomes.
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Concluding remarks and future prospects
Accumulating evidence of the importance of miRNAs role in the skeleton has prompted
the development in profiling approaches to identify miRNAs associated with skeletal diseases, as
well as the development of new computational tools and high throughput screening techniques to
discover novel miRNA-target interactions. With these developments, targeting microRNA-based
regulatory mechanisms is an emerging therapeutic strategy.

In the field of miRNA-based therapeutics, developments have focused on designing and
delivering stable mimetics or inhibitors for sustained alteration of miRNA activity in vivo. For
augmenting the stability of miRNA mimics or inhibitors, oligonucleotide sequences are
subjected to chemical modifications including 2-O-methyl (2’-O-Me), locked nucleic acid
(LNA), and peptide nucleic acid (PNA) variants. For efficient delivery of chemically modified
miRNA mimics or inhibitors, currently used synthetic systems include lipid-based complexes,
polyethylenimine (PEI), polylactide-co-glycolide (PLGA) based particles, and modified
peptides. Naturally occurring polymers that seem to enhance cell uptake, such as chitosan,
protamine, atelocollagen and cell-penetrating peptides (CPP) have also been used for delivery of
miRNA therapeutics [312]. With designing efficient delivery systems, focus has now shifted
towards technology for cell/tissue specific delivery.

Currently, two clinical trials for miRNA-based therapeutics against hepatitis C and cancer
are being conducted. The most advanced clinical trial to date examines the therapeutic potential
of miR-122 inhibitor against the hepatitis C virus. miR-122 is abundantly expressed in liver, and
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miR-122 binds to two closely spaced target sites within the 5’ non-coding region of the hepatitis
C virus genome, that is necessary to maintain the abundance of viral RNA. Sequestration of
miR-122 using anti-miR reduces the virus replication. In this application, two anti-miR-122
therapeutics have been developed, one with an N-acetylegalactosamine (GalNAC) conjugate
(Regulus Therapeutics) and the other with an LNA conjugate (Santaris Pharma). Of these, the
LNA-anti-miR-122 termed Miravirsen has cleared phase I and is undergoing phase II of clinical
trials [313].

The second microRNA therapeutic under clinical trial is MRX34, which is a miR-34a
mimic developed against primary liver cancer and solid cancers that metastasize to liver. MRX34
was developed by miRNA Therapeutics Company, and is in phase I of clinical trials. Decrease in
expression of miR-34a has been shown in cervical cancer, ovarian cancer, glioblastoma,
hepatocellular carcinoma, colon cancer, non-small cell lung cancer (NSCLC). miR-34a, a tumor
suppressor, has been shown to repress oncogenes such as CDK4 (cyclin dependent kinase 4) that
promotes cell cycle progression; BCL2 (B cell lymphoma 2) that blocks apoptosis, and Wnt1/3
that promotes cell proliferation. Decreased miR-34a expression has been shown in cervical
cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, colon cancer, non-small cell
lung cancer (NSCLC). Increasing levels of miR-34a in cancer cells using MRX34 antagonizes
key hallmarks including self-renewal and migratory potential [314, 315].

For tissue specific delivery of miRNA-therapeutics to the skeleton, biomaterials,
nanoparticles and peptide-mediated approaches have been developed. As an example of
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biomaterial based approach, one recent study demonstrated repair of a mouse critical size
calvarial defect using a polyglycerol sebacate (PGS) scaffold loaded with BMSCs transfected
with anti-miR-31. Inhibition of miR-31 was shown to promote osteoblastic differentiation and
function, leading to enhanced bone formation [316].

For modulation of mesenchymal stem cells (MSCs), nanoparticle and gelatin nanofibersbased strategies have been developed for miRNA delivery [317, 318]. For example, gelatin
nanofibers scaffolds incorporating miR-29a inhibitor improved extracellular matrix production
by pre-osteoblasts. In osteoblasts, miR-29 family has been previously shown to inhibit
extracellular matrix production and regulate Wnt signaling. Inhibition of miR-29 signaling in
pre-osteoblasts promotes collagen and osteonectin synthesis, upregulates Igf1 and Tgfβ mRNA
expression, and promotes osteoblastic commitment [213, 219, 318]. Another study used
nanoparticles tagged to a photolabile linker to deliver miR-148b mimics to human adipose
derived stem cells (hASCs). miR-148b mimics incorporated scaffolds when seeded with hASCs
demonstrate improved bone formation at the critical size calvarial defect in vivo [319]. An
example of peptide-mediated approaches for intracellular miRNA delivery included an argininerich cell penetrating peptide to deliver miR-29b mimic to human mesenchymal stem cells in
vitro. This delivery greatly improved transfection efficiency and promoted their osteoblastic
differentiation [320].

Strategies to enhance miRNA delivery to osteoblasts and osteoclasts have also been
recently developed. For example, D-Asp8 peptide conjugated liposomes were developed to
deliver anti-miR-148a to osteoclasts. D-Asp8, consisting of eight repeating sequences of
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aspartate, provides enhanced specificity for binding to crystallized hydroxyapatite on bone
resorptive surface. This innovative targeting system was capable of downregulating miR-148a in
osteoclasts, resulting in reduced bone resorption in vivo. Non-detectable or extremely low levels
of tagged-anti-miR-148a was observed in other tissues [321]. Interestingly, increased miR-148a
expression has been associated with osteoporosis in other studies, providing a potential for use of
miR therapeutics [144].

In conclusion, recent advances in understanding the function of miRNAs in the skeleton
suggest their potential as therapeutic targets and as therapeutic entities. Since miRNAs primarily
function in fine-tuning multiple signaling cascades, understanding the role of miRNA in vivo by
using transgenic mouse models will be crucial. Moreover, transgenic miRNA mouse models can
also prove valuable for testing miRNA-based therapeutics. Moving forward, with the implication
of miRNA-SNPs in skeletal diseases and identification of miRNAs important for bone mass, we
believe that miRNAs will play a crucial role in for personalized diagnostics and therapeutics for
osteoporosis.
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